

Comparing acupoint catgut embedding and acupuncture therapies for simple obesity A protocol for systematic review and meta-analysis

Hui Yan Zhao, BD^{a,b}, Sungha Kim, KMD, PhD^b, Mi Ju Son, KMD, PhD^{b,*} 10

Abstract

Background: This systematic review aimed to assess the effectiveness and safety of acupoint catgut embedding (ACE), which is widely used in simple obese patients.

Methods: Nine electronic databases and 2 trial registries were searched from inception to September 2021 without language limitations. All randomized controlled trials involving ACE therapies for simple obesity were included. Assessment of Cochrane's risk of bias and meta-analysis, as well as GRADE evaluation, were also performed.

Results: A total of 73 randomized clinical trials involving 5872 participants were included. The overall risk of bias was high or unclear. ACE showed higher efficacy in total effective rate, body mass index, and body weight than manual acupuncture. In addition, ACE is more beneficial in total effective rate than electroacupuncture (EA). Moreover, combination therapy of ACE with EA is more effective in total body mass index and body weight than EA alone.

Conclusions: Despite some potential improvement, the evidence regarding the effectiveness and efficacy of ACE for simple obesity is inconclusive due to the poor quality of evidence. Further well-designed randomized controlled trials are needed to confirm the effectiveness of ACE for simple obesity.

Abbreviations: AA = auricular acupressure, ACE = acupoint catgut embedding, BFP = body fat percentage, BMI = body mass index, BW = body weight, CIs = confidence intervals, CMT = Chuna manual therapy, EA = electroacupuncture, GRADE = Grading of Recommendations Assessment, Development and Evaluation, HC = hip circumference, MA = manual acupuncture, MD = mean difference, RCTs = randomized controlled trials, RRs = risk ratios, SMD = standardized mean difference, SR = systematic reviews, TC = total cholesterol, WC = waist circumference, WHR = waist-hip ratio.

Keywords: acupoint catgut embedding, meta-analysis, simple obesity, systematic review, thread embedding

1. Introduction

Obesity has become a worldwide epidemic with rapidly increasing morbidity and a huge burden on personal and public health.^[1,2] Simple obesity is defined as increased body weight (BW) and accumulation of body fat without obvious disease. A recent study stated that 51% of the population will develop simple obesity by 2030 according to the National Health and Nutrition Examination Survey in U.S.^[3] Moreover, simple obesity is associated with a major risk of comorbid chronic diseases, such as cardiovascular diseases, cancer, and diabetes.^[4] Therefore, with the rapid development of medical technology, the treatment of simple obesity has become a targeted intervention based on the individual differences of patients.^[5]

MJS and SK contributed equally to this study.

This work was supported by the Ministry of Health & Welfare, Republic of Korea [Grant Number HF20C0208]. The funder had no role in this review, preparation of the manuscript, or decision to publish.

The authors have no conflicts of interest to disclose.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Supplemental Digital Content is available for this article.

Currently, obesity treatment methods mainly include lifestyle modification, drugs, and surgical treatment.^[6] However, changing one's lifestyle and engaging in physical exercise require high self-control and economic resources.^[7] Furthermore, the long-term use of anti-obesity drugs, namely rimonabant, is restricted in many countries because it can cause anxiety and depression.^[8] Thus, pharmacological and non-pharmacological treatments have not achieved satisfactory results.

Acupoint catgut embedding (ACE) is an alternative medicine that has been widely used for treating a variety of diseases, such as obesity, stomach disease, and migraine.^[9] Multiple studies have demonstrated the amelioration of weight after the use of ACE.^[10,11] Although two systematic reviews (SR)s were

How to cite this article: Zhao HY, Kim S, Son MJ. Comparing acupoint catgut embedding and acupuncture therapies for simple obesity: A protocol for systematic review and meta-analysis. Medicine 2022;101:51(e31531).

Received: 26 July 2022 / Received in final form: 15 September 2022 / Accepted: 19 September 2022

http://dx.doi.org/10.1097/MD.000000000031531

^a Korean Convergence Medical Science, University of Science and Technology (UST), School of Korea Institute of Oriental Medicine, Daejeon, Republic of Korea, ^b KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.

^{*} Correspondence: Mi Ju Son, KM Science Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon 34054, Republic of Korea (e-mail: mj714@kiom.re.kr).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

conducted to establish the effect of ACE on obesity,^[12,13] there were language limitations. Additionally, many randomized controlled trials (RCTs) of ACE and related therapies published in recent years have not been included in previous SRs. For example, an RCT published in 2020 found that participants who received ACE experienced a significant reduction in BW.^[14,15] Of note, there are many kinds of alternative medicine interventions, which can treat simple obesity, such as Chuna manual therapy (CMT), auricular acupressure (AA), manual acupuncture (MA), and electroacupuncture (EA).^[16,17] Therefore, it is important to perform a SR to appraise and compare all available evidence and to reach a better conclusion about ACE. The specific research questions addressed herein were as follows: Is ACE associated with reduction in obesity compared with MA or EA? and In clinical practice, is the combination of ACE and other therapies a good choice for treating obesity?

2. Materials and Methods

2.1. Protocol registration

This review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.^[18] The checklist was shown in Table S1, Supplemental Digital Content 1, http://links.lww.com/MD/H822. The protocol was published in Medicine®: Case Reports and Study Protocols (Medicine Case Reports and Study Protocols 2021;2:11:e0194, doi: 10.1097/MD9.00000000000194).^[19]

2.2. Inclusion criteria for study selection

2.2.1. Type of study. Only RCTs of ACE for obesity without restrictions on publication status were eligible for inclusion. Trials were excluded based on the following criteria: animal studies, literature review, and non-RCTs.

2.2.2. Type of participants. Participants were diagnosed with simple obesity using clearly defined or internationally recognized criteria, regardless of sex, age, or race.

2.2.3. Type of intervention. ACE therapy alone or in combination with other interventions, such as MA, EA, AA, cupping therapy, and CMT. Other interventions, such as Western medicine, herbal medicine, usual care and practice, and sham ACE, were excluded.

2.2.4. Type of comparisons. The comparison interventions included MA, EA, AA, cupping therapy, and CMT.

2.2.5. Treatment period. Not specified.

2.2.6. Outcome measures. Total effective rate, body mass index (BMI), BW, waist circumference (WC), hip circumference (HC), waist-hip ratio (WHR), and body fat percentage (BFP) were the primary outcomes. Levels of metabolic markers, such as triglyceride and total cholesterol (TC) levels, and adverse events were considered the secondary outcomes.

2.3. Search method for identification of studies

2.3.1. Electronic data sources. The following nine electronic databases were searched to identify RCTs published from inception to September 2021: PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health Literature, Oriental Medicine Advanced Searching Integrated System, Science-ON, KoreaMed, China Network Knowledge Infrastructure, and CiNii. We did not apply language restrictions.

2.3.2. Searching other resources. The reference lists of potentially missing eligible studies were searched from the ongoing trial databases such as Clinicaltrials.gov and the World Health Organization International Clinical Trials Registry Platform. The referenced reviews and retrieved articles of all included studies were scanned.

2.3.3. Search strategy. The following keywords were used: obesity (e.g., "obesity" or "weight gain"); catgut embedding (e.g., "catgut" or "thread"); RCT (e.g., "randomized controlled trial"). We used the search strategy described in a previous protocol.^[19]

2.4. Date collection and analysis

2.4.1. Selection of studies. Two investigators (Zhao HY and Son MJ) reviewed and screened the articles independently by checking the titles and abstracts. If there was any disagreement, either a consensus was reached or a third party (Kim S) was involved. Supplemental Digital Content 2, http://links.lww.com/MD/H823 presents a PRISMA 2020 flow diagram of the study selection process.

2.4.2. Data extraction. Two reviewers independently extracted data using a standard data extraction form. The following data were extracted: the first author, year of publication, interventions and comparison treatment, duration, follow-up, outcome measurements, results, adverse events, and other information. A third reviewer was selected to conduct a discussion and to address disagreements during the extraction process.

2.4.3. Quality assessment. The risk of bias was determined according to the Cochrane Handbook for SR of Interventions (version 6.2). Two reviewers independently assessed the following characteristics of the included studies: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting and other bias.^[20] All differences were resolved by consensus or after discussion with the third reviewer.

2.4.4. Assessment of quality of evidence. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) method was used to assess the quality of the evidence for the primary and secondary outcomes.^[21] The evidences were divided according to the four levels of evidence quality, namely high, moderate, low, and very low, in terms of the following five major domains: inconsistency, limitations, imprecision, indirectness, and publication bias.

2.4.5. Statistical analysis. All statistical analyses were performed using Reviewer Manager Software, version 5.4. (RevMan, the Cochrane Collaboration, London, England, 2020). We considered the clinical heterogeneity among studies, and a random-effects model was used to determine the estimates of treatment effects. The weights of individual trials were determined by inverse variance and Mantel-Haenszel methods for continuous and dichotomous outcomes, respectively. For continuous data, we calculated the mean difference (MD) or standardized mean difference (SMD), whereas dichotomous outcomes are expressed as risk ratios (RRs) with 95% confidence intervals (CIs). The statistical heterogeneity was analyzed using I^2 test; I^2 of 0% to 50% was considered low, 50% to 75%, serious, and >75%, very serious. Moreover, subgroup analyses were conducted to detect the potential for heterogeneity and when possible, included the type of treatment and treatment period.

3. Results

The database searches yielded 55 studies from PubMed, 172 from EMBASE, 251 from Cochrane Central Register of Controlled Trials, 54 from CINAHL, 285 from China Network Knowledge Infrastructure, 0 from CiNii, 58 from SCIENCE ON, 0 from KoreaMed, 8 from Oriental Medicine Advanced Searching Integrated System, 1 from Clinicaltrials.gov, and 4 from International Clinical Trials Registry Platform. After the duplicates were removed, 818 studies remained. After the first review, which was based on the title and abstract, 195 studies remained. A total of 195 studies were selected for full text review and data processing; 121 studies were excluded as per the pre-defined eligibility criteria. Ultimately, 73 RCTs were included (including 4 three-armed studies) in the meta-analysis.

3.1. Study characteristics

The characteristics of the included trials are listed in Table 1. All trials were conducted in China; 72 were written in Chinese and one in English. A total of 5872 patients with obesity were involved in this meta-analysis, with sample sizes ranging from 21 to 200, and the duration of treatment was from 12 days to 6 months. Fifty-five trials included patients with simple obesity;^[15,22,23,25-28,32-34,36-41,43-46,49-51,54,56-59,61-63,65-67,69-73,75-80,82-90,92] six included patients with abdominal obesity;^[14,31,47,52,68,74] one included a patient with central obesity;^[24] one included a patient with lower body obesity;^[91] the remaining ten trials did not mention the type of obesity;^[29,30,35,42,48,53,55,60,64,81] The other detail of treatment was showed in Supplemental Digital Content 3, http://links.lww.com/MD/H824.

All included studies were divided into seven groups based on the intervention and comparison groups: ACE versus MA (n = 30),^[14,22,27,29,31,32,34,37,44,45,48–51,56–58,60–62,64,69,72,73,76,84,85,88–90] ACE versus EA (n = 25),^[15,25,28,30,36,39–41,43,46,47,52–54,59,63,65,71,74,79,82,83,86,87,91] ACE plus MA versus MA (n = 6),^[26,31,38,42,50,78] ACE plus EA versus EA (n = 10),^[23,24,33,47,54,67,70,75,80,92] ACE plus AA versus AA (n = 2),^[35,77] ACE plus CMT versus CMT (n = 3),^[66,68,81] and ACE plus cupping therapy versus cupping therapy (n = 1).^[55]

3.2. Quality of the included studies

Figure 1 shows the risk of bias of the included studies. All 73 studies mentioned randomization in the trials; however, 16 studies used the visiting sequence, which is considered to have high risk of bias for random sequence generation;^{28,43,53,54,58,59,61,62,65,70,73,75,82,83,87,88]} 36 studies provided information on allocation concealment, [14,15,22-24,28,29,31,35-40,42-46,52,54,57,63,68,74-76,79,80,83,85-87,90-92] and the remainder of the studies did not report allocation concealment, resulting in an unclear risk of bias. All trials were judged to have a high risk of bias with respect to the blinding of participants, given that it was impossible to blind the participants in studies comparing the ACE intervention with other therapies. Considering that the outcomes of all evaluations are objective in the study, we judged the outcome measurement as being unlikely to be affected by the lack of blinding. Incomplete outcome data were reported in five studies owing to the number of drop-outs in the trial,^[14,36,64,79,80] and no study reported data with a low risk of bias. All RCTs had unclear bias in terms of blinding.

3.3. Synthesis of results

3.3.1. ACE versus MA.

3.3.1.1. Total effective rate. Twenty-nine studies^{[14,22,27,29,31,32,34,37,44,48–51,56–58,60–62,64,69,72,73,76,84,85,88–90] out of 30 including 2100 participants (1060 in the experiment group and 1040 in the comparison group) were included in the meta-analysis to synthesize the total effective rate. As shown}

in Figure 2A, the pooled results showed that ACE was more effective than MA (RR = 1.12 [1.07, -1.18]; P < .00001, $I^2 = 45\%$).

3.3.1.2. *BMI.* Eighteen studies^{[14,22,29,34,37,44,45,48–50,57,64,72,76,85,88–90]</sub> assessed the benefit of ACE in reducing the BMI. However, the results showed serious heterogeneity ($l^2 = 86\%$). We conducted a subgroup analysis, and the pooled result showed that after using similar acupoints ST25, ST36, ST40, SP6, SP9, and CV12, ACE was more effective than MA in reducing BMI (MD = -1.06 [-1.72, -0.39]; P = .002, $l^2 = 0$) (Fig. 2B).}

3.3.1.3. *BW.* We pooled data from 19 studies^[14,22,27,31,34,37,44,45,48,49,56,57,64,72,76,85,88-90] reporting on BW between the intervention and comparison groups. We found that ACE was beneficial for reducing BW (n = 1298, MD = -2.28 [-3.16, -1.41]; *P* < .00001, *I*² = 51%) (Fig. 2C).

3.3.1.4. WC. We included of 15 the results studies^[14,27,34,37,44,48,49,56,64,72,76,85,88–90] and demonstrated а significant difference in the WC data between the intervention and control groups with moderate heterogeneity ($I^2 = 68\%$). We conducted a subgroup analysis, and the results showed that ACE was more effective than MA in reducing WC when using similar acupoints such as ST25, ST36, ST40, SP6, SP9, and CV12 (MD $= -4.53 [-5.88, -3.18]; P < .00001, I^2 = 0\%)$ (Fig. 2D).

3.3.1.5. *HC.* Comparisons of 10 studies^[27,34,37,48,49,72,85,88–90] showed that ACE was significantly different with high heterogeneity ($I^2 = 73\%$). When we used a similar acupoint routine as mentioned above, the results had no heterogeneity (MD, -3.08 [-5.20, -0.96]; P = .004, $I^2 = 0$).

3.3.1.6. WHR. On pooling the studies^[34,50,88,90] that examined the reduction in obesity with ACE versus MA, a pooled SMD of -0.13 ([-0.34, 0.08]; P = .22, $I^2 = 0$) was obtained in favor of ACE.

3.3.1.7. *BFP.* Six studies,^[14,29,49,50,88,90] with 506 participants, were pooled for this analysis. The pooled results showed serious heterogeneity ($I^2 = 90\%$). A subgroup analysis of data reported after using similar acupoints showed that ACE was more effective than MA (MD = -1.78 [-2.57, 0.99]; P < .00001, $I^2 = 0\%$).

3.3.2. ACE versus EA.

3.3.2.1. Total effective rate. Twenty-four studies^[15,25,28,30,36,40,41,43,46,47,52-54,59,63,65,71,74,79,82,83,86,87,91] reported data on ACE versus EA. The result showed a significant difference between ACE and EA (n = 1825, RR = 1.06 [1.02, 1.10]; P = .005, $I^2 = 24\%$) (Fig. 3).

3.3.2.2. BMI. BMI was assessed in 20 studies, $^{[15,25,28,30,36,40,43,46,47,52-54,63,65,74,79,82,83,86,87]}$ and borderline differences were observed between the ACE and EA (n = 1505, MD = -0.30 [-0.80, 0.20]; P = .23, $I^2 = 70\%$).

3.3.2.3. *BW.* We compared the effects of ACE and EA on BMI data.^[15,25,28,36,40,43,46,47,52,53,63,65,74,82,83,86,87] There was no significant difference between the two groups (n = 1246, MD = 0.18 [-0.85, 1.21]; P = .73, $I^2 = 20\%$).

3.3.2.4. WC. In total, 14 studies^[15,25,36,40,43,46,47,52,54,63,65,74,82,86] assessed WC with ACE and with EA alone, and there were no significant differences in their effect (n = 1029, MD = -0.86 [-1.84, 0.11]; P = .08, $I^2 = 19\%$).

3.3.2.5. *HC.* The results of nine studies^[25,40,43,46,47,52,54,63,74] showed borderline differences between the two groups (n = 698, MD = 0.51 [-0.90, 1.91]; P = .48, $I^2 = 62\%$).

3.3.2.6. *WHR.* Eight studies^[30,40,43,47,52,54,63,87] reported reduced outcomes for obesity with ACE and EA. The pooled result did

Table 1 Characteristics of included studies.	of included st	udies.								
First author (year) Country	Type of obesity	Age (mean ± SD) (range)	Duration	Duration Acupoints of ACE	Experimental intervention	Control intervention	Sample size	Outcome measure	Effects estimates	Adverse events
Chen (2007) China ^[22]	Simple obesity	(A) 43.1 ± 13.6 (n.r.) (B) 44.6 ± 10.3 (n.r.)	1 mo	ST34, CV12, ST25, CV9, ST40	(A) ACE	(B) MA	(A) 40 (B) 40	Total effective rate BMI BW BW FBG FINS HOMA-IR TNE-C	RR, 1.03 [0.88, 1.20], <i>P</i> = .72 MD, -0.59 [-1.92, 0.74], <i>P</i> = .38 MD, 1.48 [-1.07, 4.03], <i>P</i> = .26 MD, -0.01 [-0.21, 0.19], <i>P</i> = .92 MD, 0.51 [-0.08, 1.10], <i>P</i> = .99 MD, 0.08 [-0.11, 0.27], <i>P</i> = .41 MD, 0.035 0.777 <i>P</i> = .45	u.r.
Chen (2010) China ²⁴	Simple obesity and central obesity	(A) 45.72 ± 10.02 (n.r.) (B) 44.83 ± 10.13 (n.r.)	8 wk	GB26, CV12, ST25, CV9, ST40	(A) ACE plus EA	(B) EA	(A) 55 (B) 55	: rate	RR, 1.0.41 (0.89, 1.21), $P = .64$ MD, -0.99 [-2.50 , 0.52], $P = .20$ MD, -0.07 [-0.39 , 0.25], $P = .20$ MD, 0.04 [-0.09 , 0.17], $P = .53$ MD, 0.02 [-0.13 , 0.17], $P = .53$ MD, 0.02 [-0.13 , 0.17], $P = .53$	n.r.
Chen (2010) China ^[23]	Simple obesity	(A) 31.23 ± 9.46 (n.r.) (B) 33.37 ± 12.08 (n.r.)	3 mo	ST21, ST25, SP15, ST28, ST37	(A) ACE plus EA	(B) EA	(A) 30 (B) 30	e rate	RM, 1.04 $(0.90, 1.20)$, $P = .57$ MD, 0.46 $[-0.71, 1.63]$, $P = .44$ MD, 0.60 $[-3.34, 4.54]$, $P = .77$ MD, $-0.43 [-3.49, 2.63]$, $P = .77$ MD, $-0.43 [-3.49, 2.63]$, $P = .78$	Syncope
Chen (2014) China ^[25]	Simple obesity	(A) 34.3 ± 3.2 (22–59) (B) 35.2 ± 3.6 (22–60)	3 mo	CV6, CV4, ST25, SP15, CV12, CV10, ST36, SP9, BL18, BL20, BL21, BL23, BL25	(A) ACE	(B) EA	(A) 28 (B) 28	Total effective rate BMI BW WC HC	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \begin{array}{c} \end{array} \\ \begin{array}{c} \end{array} \\ \begin{array}{c} \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} $	Vertigo, fatigue, 1 vomiting
Chen (2015) China ^[26]	Simple obesity	n.r. ± n.r. (18–46)	12 wk	LI11, CV13, CV12, CV10, ST25, SP15, ST24, ST26, CV4, ST36, ST40. SP6	(A) ACE plus MA	(B) MA	(A) 40 (B) 40	Total effective rate	RR, 1.12 [0.95, 1.33], <i>P</i> = .18	n.r.
Chen (2016) China ^[27]	Simple obesity	42.8 ± 2.9 (19–68)	8 WK	ST21, ST25, CV6, ST40	(A) ACE	(B) MA	(A) 47 (B) 47	Total effective rate BW WC HC	RR, 1.15 [1.00, 1.33], $P = .05$ MD, -4.60 [-6.76 , -2.44], $P < .0001$ MD, -5.80 [-9.66 , -1.94], $P = .003$ MD, -7.60 [-10.29 , -4.91], $P < 00001$	n.r.
Chen (2018) China ^[28]		Simple obesity (A) 35.83 ± 8.54 (21-52) (B) 35.37 ± 8.91 (23-56)	2 mo	CV12, ST25, SP15, GB26, ST36, ST40, SP6, BL18, BL21, BL23	(A) ACE	(B) EA	(A) 30 (B) 30	Total effective rate BMI BW ALT TG	RR, 1.04 (0.80, 1.36), <i>P</i> = .75 MD, -0.98 [-1.71, -0.25], <i>P</i> = .008 MD, -3.25 [-7.19, 0.69], <i>P</i> = .11 MD, -3.29 [-10.99, 3.01], <i>P</i> = .25 MD, -0.27 [-0.57, -0.071, <i>P</i> = .03	IJ.r.
Chen (2019) China ^[29]	Obesity	(A) 39.31 ± 14.13 (16-64) (B) 37.51 ± 13.03 (17-64)	10 wk	SI4, BL22, BL17, GB26, ST25, ST28, ST40	(A) ACE	(B) MA	(A) 35 (B) 35	Total effective rate BMI BFP TC TG HDI - C	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \end{array}\\ \end{array}\\ \end{array}\\ \end{array}\\ \end{array} \\ \begin{array}{c} \begin{array}{c} \end{array}\\ \end{array}\\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array}\\ \end{array} \\ \end{array} \\ \begin{array}{c} \begin{array}{c} \end{array}\\ \end{array}\\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array}\\ \end{array}\\ \end{array} \\ \begin{array}{c} \end{array}\\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array}\\ \end{array}\\ \end{array} \\ \begin{array}{c} \end{array}\\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array}\\ \end{array} \\ \end{array} \\$	
Chu (2014) China ^[30]	Obesity	29 ± 5 (22−48) (B) 27 ± 5 (21−41)	2 mo	CV13, CV12, CV10, CV7, CV9, CV4, CV6, ST25, ST24, ST26, SP14, GB26, GB27, L114, TE13, L14, L111, GB31, GB32, ST34, ST36, ST37, ST40, SP6, SP9	(A) ACE	(B) EA	(A) 25 (B) 25	Total effective rate BMI WHR	RR, 0.89 [0.61, 1.30], <i>P</i> = .55 MD, -1.42 [-3.85, 1.01], <i>P</i> = .25 MD, 0.00 [-0.19, 0.19], <i>P</i> = 1.00	u.r.

4

Medicine

(Continued)

Table 1 (Continued)										
First author (year) Country	Type of obesity	Age (mean ± SD) (range)	Duration	Duration Acupoints of ACE	Experimental intervention	Control intervention	Sample size	Outcome measure	Effects estimates	Adverse events
Deng (2014) China ^[31]	Simple obesity and abdominal obesity	(A) 33 ± 8 (n.r.) (B) 33 ± 7 (n.r.) (C) 32 ± 7 (n.r.)	45 d	CV12, ST25, CV7, TE6, CV4, ST36	(A) ACE (B) ACE plus MA	(C) MA	(A) 30 (B) 30 (C) 30	Total effective rate BW Total effective rate	ACE vs MA RR, 1.08 [0.62, 1.89], P = .80 MD, 2.38 [-1.44, 6.20], P = .22 ACE plus MA vs MA RR, 1.77 [1.12, 2.79], P = .01	חיג
Ding (2006) China ^[32]	Simple obesity	Simple obesity n.r \pm n.r. (16–46)	2 mo	CV12, ST25, ST40, LI11	(A) ACE	(B) MA	(A) 65 (B) 64	BW Total effective rate	MD, -2.24 [-5.15, 0.67], <i>P</i> = .13 RR, 1.08 [0.94, 1.23], <i>P</i> = .27	n.r.
Fan (2010) China ^[33]	Simple obesity	(A) 31.38 ± 6.71 (18-55) (B) 32.63 ± 6.78 (16-54)	2 mo	CV12, ST25, CV6, CV4, ST34, ST36, SP4, BL15, BL20	(A) ACE plus EA	(B) EA	(b) 04 (A) 40 (B) 40	Total effective rate	RR, 1.17 [0.94, 1.44], <i>P</i> = .16	u.r.
Ge (2015) China ^[34]	Simple obesity	Simple obesity n.r. ± n.r. (n.r.)	8 XX	ST21, ST25, BL17, ST40	(A) AGE	(B) MA	(A) 40 (B) 40	Total effective rate BMI BMU BW WHR WHR TG TC LDL-C HDL-C FBG FIBG	RR, 1.03 [0.90, 1.18], $P = .69$ MD, -0.34 [-3.20 , 2.55], $P = .82$ MD, -0.13 [-4.04 , 3.78], $P = .95$ MD, 1.22 [-3.02 , 5.46], $P = .57$ MD, 1.27 [-1.95 , 4.49], $P = .74$ MD, 0.00 [-0.44 , 0.44], $P = 1.00$ MD, 0.03 [-0.05 , 0.11], $P = .48$ MD, 0.03 [-0.04 [-0.17 , 0.09], $P = .62$ MD, -0.04 [-0.17 , 0.09], $P = .62$ MD, -0.04 [-0.08 , 0.01], $P = .64$ MD, -0.04 [-0.08 , 0.00], $P = .64$	л.г.
Guo (2011) China ^[35]	Obesity	(A) 42.73 ± 8.31 (n.r.) (B) 41.53 ± 6.83 (n.r.)	3 mo	CV12, CV9, ST25, SP15, BL20, BL21, ST40, ST36	(A) ACE plus AA	(B) AA	(A) 30 (B) 30	Total effective rate BMI BW WC	MDL, 0.14 [-0.24 , 0.234], $P = 3.47$ RR, 1.35 [1.02 , 1.79], $P = .04$ MDL, -1.70 [-2.74 , -0.66], $P = .001$ MDL, -3.76 [-9.89 , 2.37], $P = .23$ MDL, -3.70 [-6.51 , -0.89], $P = .010$ MDL, -3.70 [-6.51 , -0.29], $P = .010$	u.r.
Guo (2013) China ^[36]	Simple obesity	(A) 34.82 ± 5.56 (n.r.) (B) 33.18 ± 7.68 (n.r.)	2 mo	CV12, ST21, ST25, CV9, BL18, LR8, ST36, ST40, LR3	(A) ACE	(B) EA	(A) 28 (B) 28	Total effective rate BMI BW	MND, 7–2:20 (2020), 70–1:10 MND, 1200 (2083, 1.201), <i>P</i> = 1:00 MD, -0.13 [-1.32, 1.06], <i>P</i> = .83 MD, 0.09 [-435, 4:53], <i>P</i> = .97 MND, 0.78 [-5-13, 5, 4:53], <i>P</i> = .60	u.n n
Guo (2014) China ^{I37}	Simple obesity	(A) 34.37 ± 9.16 (n.r.) (B) 30.68 ± 8.33 (n.r.)	2 mo	GB26, ST25, ST36, ST40, SP6, SP9, SP15, CV4, CV12, Ll11, ST37	(A) ACE	(B) MA	(A) 35 (B) 34	Total effective rate BMI BW WC	RR, $0.70 = 0.720$, $0.200 = 1.200$, $0.200 = 1.200$, $0.200 = 1.000$, $0.230 = 0.200$, 0.421 , $P = .100$, $MD_1 = -2.34 = [-7.89, 2.211]$, $P = .27$, $MD_2 = -4.17 = [-8.13, -0.211]$, $P = .04$, $MD_2 = .04$,	n.r.
Hou (2016) China ^[38]	Simple obesity	(A) 27.1 ± 1.5 (18−46) (B) 26.8 ± 1.2 (19−44)	3 wk	LI11, CV13, CV12, SP15, ST25, ST24, CV4, ST36, ST40, SP6	(A) ACE plus MA	(B) MA	(A) 68 (B) 68	Total effective rate WHR BFP TG	$\begin{array}{c} \text{WR}_{11,12} = \frac{1}{12} \sum_{i=1}^{12} \sum_{i=1}^{12}$	л.п Т.п
Hu (2013) China ^[39]	Simple obesity	(A) n.r. ± n.r. (22–53) (B) n.r. ± n.r. (21–54)	4 mo	SPG, ST36, ST40, ST36, SP15, CV12, CV6, ST28	(A) ACE	(B) EA	(A) 30 (B) 30	LDL-C	$\begin{array}{l} \text{MD}, -0.50 \left[-0.38, -0.02 \right], P = .00 \\ \text{MD}, -0.50 \left[-0.38, -0.03 \right], P = .04 \\ \text{MD}, -0.06 \left[-0.47, 0.35 \right], P = .77 \\ \text{MD}, 0.06 \left[-0.14, 0.26 \right], P = .56 \\ \text{MD}, -0.54 \left[-0.76, -0.32 \right], P < .00001 \end{array}$	л.п. Т

Table 1 (Continued)										
First author (year) Country	Type of obesity	Age (mean ± SD) (range)	Duration	Duration Acupoints of ACE	Experimental intervention	Control intervention	Sample size	Outcome measure	Effects estimates	Adverse events
Hu (2014) China ^{40]}	Simple obesity	 (A) 33.48 ± 3.38 (20-58) (B) 37.26 ± 4.64 (21-60) 	4 mo	SP9, ST40, SP6, GB26, ST25, SP15, CV12, CV4, ST28, BL20, BL22, ashi acupuncture point	(A) ACE	(B) EA	(A) 30 (B) 30	Total effective rate BMI BW BW WH MC WHR WHR TG TG HDL-C LDL-C	RR, 1.04 [0.84, 1.29], $P = .72$ MD, 0.17 [-0.61 , 0.95], $P = .67$ MD, 1.135 [-0.22 , 2.92], $P = .09$ MD, -2.34 [-3.97 , -0.71], $P = .005$ MD, -0.06 [-0.91 , 0.79], $P = .89$ MD, -0.05 [-0.09 , -0.01], $P = .066$ MD, -0.03 [-0.22 , 0.16], $P = .62$ MD, -0.03 [-0.22 , 0.16], $P = .66$ MD, -0.02 [-0.24 , 0.20], $P = .66$	Contusion and nodule formation
Huang (2007)	Simple obesity	r n.r. ± n.r. (18—40)	4 wk	ST25, ST24, ST26, CV9, CV12,	(A) ACE	(B) EA	(A) 30	Lepuir Total effective rate	мы, – ч. с.э. [– т. э. т. ч. от.], <i>н</i> = . о4 RR, 1.32 [0.96, 1.80], <i>P</i> = .09	n.r.
Huang (2009) China ^{4/2}	Obesity	(A) 28.00 ± 5.87 (n.r.) (B) 27.30 ± 6.02 (n.r.)	с 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	ST21, ST29, CV4, SP10, ST40, SP6	(A) AGE plus MA	(B) MA	9 8 8 9 8 9	Total effective rate BMI BW BW WC HC FSH LH E2 E2	RR, 1.17 [0.95, 1.43], $P = .14$ MD, 1.44 [0.45, 2.43], $P = .004$ MD,4.62 [-9.87, 0.63], $P = .008$ MD, -2.33 [-6.31, 1.65], $P = .25$ MD, -2.26 [-5.16, 0.64], $P = .13$ MD, -0.26 [-1.61, 1.09], $P = .71$ MD, 0.45 [-0.60, 1.50], $P = .40$ MD, 0.110.00 [64.44, 155.56], $P < .00001$	Syncope and nodule formation
Huang (2009) China ⁽⁴³	Simple obesity	Simple obesity n.r. ± n.r. (18–65)	8 wk	CV12, ST25, SP15, CV9, CV4, ST36, ashi acupuncture point	(A) ACE	(B) EA	(A) 30 (B) 30	T Total effective rate BMI BW WC WC HC TC TC HDL-C	MD, $-0.08 [-0.27, 0.11]$, $P = .41$ RR, 1.04 $[0.86, 1.25]$, $P = .69$ MD, 0.81 $[-0.72, 2.34]$, $P = .30$ MD, 0.65 $[-3.56, 4.86]$, $P = .76$ MD, $2.77 [-1.86, 7.40]$, $P = .24$ MD, $1.27 [-1.98, 4.52]$, $P = .44$ MD, $0.02 [-0.10, 0.05]$, $P = .20$ MD, $-0.03 [-0.40, 0.34]$, $P = .38$ MD, $0.015 [-0.18, 0.048]$, $P = .38$ MD, $-0.09 [-0.19, 0.01]$, $P = .08$	Nodule formation and vascular trauma
Huang (2019) China ⁽⁴⁴⁾	Simple obesity	 (A) 34.36 ± 7.56 (n.r.) (B) 35.21 ± 7.25 (n.r.) 	8 wk	CV12, ST25, BL25, BL20, BL21, LR13, BL22, CV5, ST26, GB26, ashi acupuncture point	(A) ACE	(B) MA	(A) 33 (B) 33	LDL-C Total effective rate BMI BW	MD, 0.15 [-0.18 , 0.48], $P = .37$ RR, 1.50 [1.12 , 2.02], $P = .007$ MD, -2.70 [-3.74 , -1.66], $P < .00001$ MD, -2.81 [-4.13 , -1.49], $P < .0001$ MD, -2.81 [-4.13 , -1.49], $P < .0001$	u.
Huang (2020) China ⁽⁴⁵⁾	Simple obesity	(b) 38.27 ± 2.52 (21-53) (B) 37.34 ± 2.57 (B) 37.34 ± 2.57 (22-54)	3 mo	CV12, ST36, ST25, ST40, ST37	(A) ACE	(B) MA	(A) 39 (B) 39	BWI BW TC	$\begin{array}{l} \text{WD}_{1} = -2.26 \left[-3.15, -1.135 \right], P < .00001\\ \text{MD}_{1} = -2.26 \left[-3.17, -1.35 \right], P < .0001\\ \text{MD}_{1} = -5.38 \left[-9.27, -1.49 \right], P = .007\\ \text{MD}_{1} = -0.64 \left[-0.72, -0.56 \right], P < .0007\\ \text{MD}_{1} = -0.22 \left[-0.39, -0.05 \right], P = .01 \end{array}$	U.L.

Table 1 (Continued)										
First author (year) Country	Type of obesity	Age (mean ± SD) (range)	Duration	Duration Acupoints of ACE	Experimental intervention	Control intervention	Sample size	Outcome measure	Effects estimates	Adverse events
Kang (2007) China ⁽⁴⁶⁾	Simple obesity	(A) 28.74 ± 6.3 (n.r.) (B) 30.19 ± 7.97 (n.r.)	θ Ξ ε	CV12, ST25, CV6, ST37	(A) ACE	(B) EA	(A) 30 (B) 30	Total effective rate BMI BW BW HC HC FINS TC LDL LDL LDL	RR, 1.05 [0.73, 1.53], $P = .79$ MD, 0.88 [-0.81 , 5.57], $P = .31$ MD, 0.88 [-0.81 , 5.57], $P = .31$ MD, 3.55 [-3.42 , 10.52], $P = .32$ MD, -0.89 [-5.51 , 3.73], $P = .71$ MD, 1.26 [-2.48 , 5.00], $P = .51$ MD, 0.21 [-0.46 , 0.88], $P = .54$ MD, -0.15 [-5.39 , 5.09], $P = .96$ MD, -0.25 [-0.56 , 0.06], $P = .91$ MD, -0.08 [-0.45 , 0.29], $P = .93$ MD, -0.08 [-0.45 , 0.29], $P = .94$	u.r.
Lan (2016) China ^{la7}	Simple obesity and abdominal obesity	n.r. ± n.r. (22–55)	12 wk	(1) CV12, CV6, ST24, ST26, SP13, SP15, BL20, BL21 (2) CV9, BL26, ST28, SP14, GB26, ST36, ST40	(A) ACE (B) ACE plus EA	(C) EA	(A) 100 (B) 100 (C) 100 (C) 100	Total effective rate BMI BW WC WHR WHR BMI BWI BW	$\begin{array}{c} \text{MD, } -0.00 \begin{bmatrix} -0.52, 0.40 \end{bmatrix}, \ P = .80 \\ ACE \ w EA \\ \text{RR, } 0.99 \begin{bmatrix} 0.95, 1.03 \end{bmatrix}, \ P = .65 \\ \text{MD, } 0.57 \begin{bmatrix} -0.37, 1.51 \end{bmatrix}, \ P = .23 \\ \text{MD, } 0.57 \begin{bmatrix} -1.47, 2.81 \end{bmatrix}, \ P = .23 \\ \text{MD, } 1.21 \begin{bmatrix} -1.47, 2.81 \end{bmatrix}, \ P = .54 \\ \text{MD, } 2.72 \begin{bmatrix} 0.84, 4.60 \end{bmatrix}, \ P = .005 \\ \text{MD, } -0.02 \begin{bmatrix} -0.04, -0.00 \end{bmatrix}, \ P = .03 \\ \text{MD, } -3.23 \begin{bmatrix} -4.20, -2.26 \end{bmatrix}, \ P = .03 \\ \text{MD, } -3.23 \begin{bmatrix} -4.20, -2.26 \end{bmatrix}, \ P = .03 \\ \text{MD, } -3.23 \begin{bmatrix} -4.20, -2.26 \end{bmatrix}, \ P = .03 \\ \text{MD, } -3.23 \begin{bmatrix} -4.20, -2.26 \end{bmatrix}, \ P = .0001 \\ \text{MD, } -8.74 \begin{bmatrix} -11.51, -5.97 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.74 \begin{bmatrix} -11.51, -5.97 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.74 \begin{bmatrix} -11.51, -5.97 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -0.0001 \\ -8.74 \begin{bmatrix} -1.51, -5.97 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.26 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.26 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \begin{bmatrix} -2.97 \\ -2.75 \end{bmatrix}, \ P < .00001 \\ \text{MD, } -8.75 \end{bmatrix}$	
Li (2005) China ⁴⁸	Obesity	(A) 38.2 ± 3.79 (13−73) (B) 36.4 ± 4.12 (21−60)	8 WK	ST21, ST24, CV6, ST40	(A) AGE	(B) MA	(A) 30 (B) 21	Total effective rate WHR WHR BMI BW WC HC CLU TG LDL-C LDL-C	who, $-0.07 (=0.35, -5.5, 9), F < .0001$ MD, $-1.28 [=3.57, 1.01], P = .27$ MD, $-0.06 [=0.08, 1.12], P = .77$ MD, $1.14 [=0.58, 2.86], P = .19$ MD, $-1.45 [=4.87, 1.97], P = .41$ MD, $-1.31 [=7.52, 4.90], P = .68$ MD, $-1.31 [=7.52, 4.90], P = .68$ MD, $-1.32 [=12.59, -1.87], P = .008$ MD, $0.37 [=3.26, 4.00], P = .84$ MD, $0.077 [=0.22, 0.56], P = .39$ MD, $0.017 [=0.02, 0.061], P = .03$ MD, $0.017 [=0.02, 0.061], P = .03$ MD, $0.017 [=0.02, 0.061], P = .03$ MD, $0.017 [=0.02, 0.061], P = .03$	
Li (2007) China ^[49]	Simple obesity	(A) 37.2 ± 5.60(n.r.) (B) 38.64 ± 6.21 (n.r.)	18 wk	 (1) CV12, ST25, SP15, ST37, ST39, ST40, L11 1, BL21, ST36 (2) CV12, BL20, ST36, SP9, SP6, BL24, BL26 (3) BL18, LR14, TE6, BL20, SP9, SP10 	(A) ACE	(B) MA	(A) 36 (B) 36	HDL-C Total effective rate BMI BW WC HC BFP	MD, 0.14 [0.06, 0.22], $P = .0007$ RR, 0.97 [0.86, 1.10], $P = .64$ MD, -1.05 [-3.11, 1.01], $P = .32$ MD, -3.10 [-6.59, 0.39], $P = .08$ MD, -3.85 [-8.18, 0.48], $P = .08$ MD, -1.60 [-6.53, 3.33], $P = .53$ MD, -1.87 [-3.98, 0.24], $P = .08$	

Table 1 (Continued)										
First author (year) Country	Type of obesity	Age (mean ± SD) (range)	Duration	Duration Acupoints of ACE	Experimental intervention	Control intervention	Sample size	Outcome measure	Effects estimates	Adverse events
Li (2009) China ^(so)	Simple obesity	34.62 ± 15.28 (22–56)	24 wk	(1) LI11, ST25, ST34, BL25, CV12, BL20, ST37 (2) BL20, ST25, CV6, ST40, CV12, SP9, ST36 (3) BL20, ST25, CV12, CV4, SP9, ST36 (4) BL23, CV4, ST36, BL20, SP9	(A) ACE (B) ACE plus MsA	(C) MA	(A) 72 (B) 70 (C) 68	Total effective rate BMI WHR BFP TC TC TC TC HDL-C LDL-C LDL-C LDL-C LDL-C LDL-C MHR BFP TC TC TC TC TC	ACE vs MA RR, 0.96 [0.86, 1.08], $P = .48$ MD, 0.05 [-1.06, 1.16], $P = .93$ MD, 0.06 [-1.19, 2.51], $P = .29$ MD, 0.06 [-1.19, 2.51], $P = .24$ MD, 0.10 [-0.07, 0.27], $P = .24$ MD, 0.10 [-0.01, 0.21], $P = .24$ MD, 0.10 [-0.01, 0.21], $P = .24$ MD, 0.01 [0.12, 0.28], $P < .00001$ MD, 0.10 [-0.01, 0.21], $P = .25$ MD, 0.00 [0.12, 0.13], $P = .25$ MD, 0.00 [-0.19, 0.14], $P = .25$ MD, 0.00 [-0.19, 0.19], $P = .100$ MD, 0.00 [-0.19, 0.19], $P = .100$ MD, 0.00 [-0.19, 0.19], $P = 1.00$ MD, 0.00 [-0.09, 0.09], $P = 1.00$ MD, 0.00 [-0.09, 0.09], $P = 1.00$ MD, 0.00 [-0.01, 0.01], $P = .06$	u.r.
Li (2012) China ⁽⁵¹⁾	Simple obesity	(A) 33.37 ± 3.68 (19−59) (B) 32.82 ± 2.96 (18−57)	6 mo	CV12, ST25, CV6, ST36, ST40	(A) ACE	(B) MA	(A) 45 (B) 45	Total effective rate	RR, 1.19 [1.02, 1.40], $P = .03$	u.r.
Li (2014) China ^{Iszl}	Simple obesity and abdominal obesity	(A) 48 ± 9 (26-65) (B) 49 ± 10 (28-62)	2 mo	GB26, ST25, SP15, CV6	(A) ACE	(B) EA	(A) 41 (B) 41	Total effective rate BMI BW WC HC WHR WHHR BFP	RR, 1.03 [0.79, 1.36], $P = .81$ MD, 0.66 [-0.94 , 2.26], $P = .42$ MD, 4.87 [-1.30 , 11.04], $P = .12$ MD, -1.84 [-6.79 , 3.11], $P = .47$ MD, 1.13 [-1.86 , 4.12], $P = .46$ MD, 0.100 [-0.03 , 0.03], $P = 1.00$ MD, -0.02 [-0.05 , 0.01], $P = .13$ MD, -1.94 [-4.54 , 0.66], $P = .13$	J.F.
Li (2016) China ^[53]	Obesity	(A) 35.2 ± 12.6 (n.r.) (B) 36.7 ± 11.8 (n.r.)	8 wk	ST21, CV12, BL20, ST36	(A) ACE	(B) EA	(A) 50 (B) 50	Total effective rate BMI RW	RR, 1.25 [1.08, 1.44], P.J. 202 MD, -0.41 [-1.82, 1.00], P= .57 MD -2.10 [-894.4.74] P= .55	n.r.
Li (2020) China ⁽¹⁴⁾	Simple obesity and abdominal obesity	(A) 32.54 ± 7.47 (22-47) (B) 31.80 ± 6.67 (21-43)	2 mo	CV12, CV9, ST25, SP15, GB25, ST28, ST36, ST40, SP9, SP6	(A) AGE	(B) MA	(A) 49 (B) 49	Total effective rate BMI BW WC WC TC TG LDL-C HDL-C	$ \begin{array}{l} \label{eq:constraint} {\rm MD} & -0.211, P=.0007\\ {\rm MD} & -1.06 \left[-1.91, -0.211, P=.017\\ {\rm MD} & -3.76 \left[-5.95, -1.571, P=.0007\\ {\rm MD} & -5.46 \left[-7.36, -3.561, P<.00001\\ {\rm MD} & -2.10 \left[-3.63, -0.571, P=.007\\ {\rm MD} & -0.248 \left[-0.65, -0.311, P<.00001\\ {\rm MD} & -0.38 \left[-0.61, -0.151, P=.001\\ {\rm MD} & -0.38 \left[-0.61, -0.151, P=.001\\ {\rm MD} & -0.38 \left[-0.61, -0.121, P<.00001\\ {\rm MD} & -0.38 \left[-0.61, -0.121, P=.001\\ {\rm MD} & -0.38 \left[-0.61, -0.21, P=.001\\ {\rm MD} & -0.38 \right] \right] \right] \right] \right] \right] \right] \right] $	- -

First author (year) Country	Type of obesity	Age (mean ± SD) (range)	Duration	Duration Acupoints of ACE	Experimental intervention	Control intervention	Sample size	Outcome measure	Effects estimates	Adverse events
Lin (2012) China ⁶⁴	Simple obesity	(A) 26.38 ± 8.41 (n.r.) (B) 27.32 ± 7.65 (n.r.) (C) 25.58 ± 9.26 (n.r.)	40 d	(1) CV12, GB26, ST36 (2) PC6, ST36, SP6	(A) ACE plus EA (B) ACE	(C) EA	(A) 30 (C) 30 (C) 30	Total effective rate BMI WC WHR WHR WHR BFP TC TC TC TC MI BMI WHR BMI TC TC TC TC TC TC	ACE vs EA RR, 0.92 [0.71, 1.19], $P = .52$ MD, 1.08 [-5.87 , 8.03], $P = .53$ MD, 1.08 [-5.87 , 8.03], $P = .76$ MD, 0.00 [-0.27 , 0.27], $P = .03$ MD, 0.00 [-0.27 , 0.27], $P = .03$ MD, 0.00 [-0.27 , 0.22], $P = .63$ MD, 0.01 [-0.38 , 0.16], $P = .42$ MD, 0.01 [-0.38 , 0.16], $P = .45$ MD, 0.016 [$(0.02, 0.30]$, $P = .03$ ACE plus E4 vs E4 vs E4 MD, -2.58 [-4.65 , -0.51], $P = .01$ MD, -2.56 [-3.92 , -1.08], $P = .29$ MD, -0.15 [-0.43 , -0.05], $P = .01$ MD, 0.22 [-0.43 , -0.05], $P = .01$ MD, -0.25 [-3.92 , -1.08], $P = .29$ MD, 0.01 [-0.15 [-0.43 , -0.05], $P = .04$ MD, 0.20 [0.01 , 0.36], $P = .04$	u.r.
Lin (2015) China ⁶⁵	Obesity	n.r. ± n.r. (20–50)	1 mo	 (1) L11, L4, TE14, CV12, ST25, CV6, ST28, BL20, GB31, ST36, ST40 (2) L10, TE6, L115, CV13, SP15, CV4, ST24, BL21, SP10, ST37, SP6 (3) L13, HT5, GB21, CV10, SP14, CV10, SP14, D105, SP14, CV10, SP14, 	(A) ACE plus cupping	(B) Cupping	(A) 50 (B) 50	Total effective rate	RR, 1.31 [1.08, 1.60], <i>P</i> = .007	Blister and nodule formation
Liu (2007) China ^{lsel}	Simple obesity	n.r. ± n.r. (18–50)	4 wk	ST25, CV4, CV9, ST36, ST40, SP6	(A) ACE	(B) MA	(A) 32 (B) 32	Total effective rate BW WC	RR, 1.04 [0.87, 1.23], <i>P</i> = .69 MD, 0.34 [-5.32, 6.00], <i>P</i> = .91 MD, 0.34 [-1.77, 2.45], <i>P</i> = .75	n.r.
Liu (2009) China ⁽⁵⁷⁾	Simple obesity	(A) 36.4 ± 1.71 (24-49) (B) 35.3 ± 2.01 (25-49)	8 wk	CV13, CV4, CV12, CV6, SP15, ST25, ST40	(A) ACE	(B) MA	(A) 30 (B) 30	Total effective rate BMI RW	RR, 1.17 [0.95, 1.43], P= .14 MD, -3.37 [-4.63, -2.11], P < .00001 MD -3.57 [-4.83, -2.11], P < .00001	n.r.
Luo (2016) China ^[58]	Simple obesity	(A) 31.6 ± 4.3 (18–50) (B) 32 8 + 3.6 (18–50)	1 mo	CV9, CV12, CV4, ST25, SP15, CV6, ST36	(A) ACE	(B) MA	(A) 30 (B) 30	Total effective rate	RR, 1.32 [1.05, 1.65], $P = .02$	n.r.
Lv (2006) China ⁽⁵⁹⁾	Simple obesity	(b) 32.52 ± 0.0 (c) 32.33 ± 10.2 (d) $16-60$ (B) 34.67 ± 12.11 (18-55) (18-55)	9 wk	CV12, CV4, SP15, CV10, CV6, ST25, ST24, ST26	(A) ACE	(B) EA	(B) 45 (B) 45	Total effective rate	RR, 1.26 [1.00, 1.58], <i>P</i> = .05	IJ.r.
Mai (2013) China ^[60]	Obesity	29.47 ± 3.61 (22–44)	3 mo	CV6, SP15, CV12, CV4, ST25, CV9	(A) ACE	(B) MA	(A) 32	Total effective rate	RR, 1.35 [1.08, 1.69], <i>P</i> = .009	n.r.
Meng (2005) China ^[61]	Simple obesity	n.r. ± n.r. (n.r.)	3 mo	ST37, ST40, SP6, SP4, ST34, ST25, RI 20, RI 21, RI 25,	(A) ACE	(B) MA	(A) 48 (A) 48 (B) 48	Total effective rate	RR, 1.12 [0.88, 1.43], <i>P</i> = .36	n.r.
Qiao (2016) China ⁶²¹	Simple obesity	Simple obesity n.r. \pm n.r. (n.r.)	2 mo	ST37, ST40, SP6, SP4, ST34, ST25, BI 20, BI 21, BI 25	(A) ACE	(B) MA	(A) 30 (B) 30	Total effective rate	RR, 1.27 [1.01, 1.61], <i>P</i> = .05	n.r.

(Continued)

Table 1 (Continued)										
First author (year) Country	Type of obesity	Age (mean ± SD) (range)	Duration	Duration Acupoints of ACE	Experimental intervention	Control intervention	Sample size	Outcome measure	Effects estimates	Adverse events
Qin (2008) China ⁽⁶³⁾	Simple obesity	(A) 37.60 ± 12.02 (n.r.) (B) 37.53 ± 10.57 (n.r.)	12 wk	CV12, CV4, ST25, ST36	(A) ACE	(B) EA	(A) 30 (B) 30	Total effective rate BMI BW WC HC	RR, 0.96 [0.80, 1.16], $P = .69$ MD, 0.28 [-0.45, 1.01], $P = .45$ MD, 2.28 [-0.46, 5.18], $P = .10$ MD, 2.36 [-0.46, 5.18], $P = .10$ MD, 0.46 [-3.64, 4.56], $P = .83$ MD, 1.07 [-1.90, 4.04], $P = .48$ MD, 0.07 L 0.03 $P = .003$	Scleroma and contusion
Ren (2009) China ^{le4}	Obesity	(A) 37.05 ± 11.10 (n.r.) (B) 35.38 ± 10.47 (n.r.)	3 mo	BL13, BL20, LR13, BL23, CV12, BL21, CV5, BL22, GB25, LU1	(A) ACE	(B) MA	(A) 22 (B) 22	Total effective rate BMI BW WC TC TG HDL-C	RR, 1.50 $(0.77, 2.94)$, $P_{-2.24}$, $P_{-2.24}$ MD, -0.27 $(-1.52, 1.08)$, $P_{-2.24}$ MD, -1.56 $(-6.20, 3.08)$, $P_{-2.70}$ MD, -6.77 $[-12.80, -0.74]$, $P_{-2.03}$ MD, -0.39 $[-1.11, 0.33]$, $P_{-2.29}$ MD, -0.13 $[-0.52, 0.40]$, $P_{-5.44}$ MD, -0.13 $[-0.52, 0.36]$, $P_{-5.46}$ MD, -0.13 $[-0.52, 0.36]$, $P_{-5.66}$ MD, -0.14 $[-0.33, P_{-5.64}]$	J.L.
Ren (2016) China ⁽⁶⁵⁾	Simple obesity	(A) 32 ± 10 (18−55) (B) 32 ± 9 (19−54)	8 wk	ST21, ST25, CV6, ST40	(A) ACE	(B) EA	(A) 36 (B) 36	Total effective rate BMI BW	RR, 1.10 [-0.25, 0.39], r = .02 RR, 1.10 [091, 1.34], P = .33 MD, -0.35 [-2.05, 1.35], P = .69 MD, -1.18 [-6.32, 3.96], P = .65 MD, -1 70 1 201 P - 28	n.r.
Shang (2016) China ^{lsel}	Simple obesity	(A) n.r. ± n.r. (28–46) (B) n.r. ± n.r. (25–45)	1 mo	BL20, LR13, SP9, ST36	(A) ACE plus Chuna	(B) Chuna	(A) 40 (B) 40	Total effective rate BMI BW WC TC TG	RR, 1.65 [1.25, 2.18], $P=$, 00001 MD, -2.20 [-2.23, -2.08], $P =$, 00001 MD, -9.90 [-14.50, -5.30], $P <$, 00001 MD, -4.10 [-6.52, -1.68], $P =$, 00009 MD, -0.60 [-0.71, -0.49], $P <$, 00001 MD, -0.39, -0.21], $P <$, 00001 MD, -0.33, -0.21], $P <$, 00001	Nodule formation contusion, fever
Shen (2012) China ^[67]	Simple obesity	(A) n.r. ± n.r. (18–55)	2 mo	ST25, BL25, CV12, BL21, CV4,	(A) ACE plus EA	(B) EA	(A) 30	Total effective rate	RR, 1.20 [0.88, 1.64], $P = .25$	n.r.
Song (2018) China ^[68]	Simple obesity and abdominal obesity	(b) 11.1 ± 11.1 (10-33) (A) 33.2 ± 2.6 (11.1) (B) 33.5 ± 2.5 (11.1)	2 m0	BL.27 ST36, SP9, LR13, BL20	(A) ACE plus Chuna	(B) Chuna	(B) 100 (B) 100	Total effective rate BMI BW BW WHR WHR FBG TC	RR, 1.41 [1.21, 1.64], $P < .00001$ MD, -3.81 [-4.18 , -3.44], $P < .00001$ MD, -9.22 [-11.79 , -6.65], $P < .00001$ MD, -6.92 [-9.31 , -4.53], $P < .00001$ MD, -6.92 [-9.31 , -4.53], $P < .00001$ MD, -0.11 [-0.16 , -0.06], $P < .00001$ MD, -0.64 [-0.71 , -0.54], $P < .00001$	Fever, contusion, nodule formation
Sun (2020) China ^[69]	Simple obesity		21 d	CV12, CV9, CV6, CV4, ST25, SP15,	(A) ACE	(B) MA	(A) 25	ا ات Total effective rate	ML, -0.31 [-0.34 , -0.28], $P < .00001$ RR, 1.19 [0.99 , 1.43], $P = .07$	n.r.
Tang (2009) China ^{rol}	Simple obesity	(B) 26.15 ± 5.9 (20–38) (A) 37.8 (21–54) (B) 36.41 (22–55)	45 d	ST24, GB26 CV12, ST25, CV6, CV4, ST34, ST36, SP4, BL15, BL20	(A) ACE plus EA	(B) EA	(B) 25 (A) 33 (B) 32	Total effective rate BMI WC WHR	RR, 1.11 [0.94, 1.32], <i>P</i> = .22 MD, -1.15 [-1.94, -0.36], <i>P</i> = .004 MD, -1.18 [-6.21, 2.45], <i>P</i> = .39 MD, -2.15 [-5.55, 1.25], <i>P</i> = .21 MD, -0.01 [-0.05, 0.03], <i>P</i> = .64	u.r.
Wang (2001) China ^[71]	Simple obesity	Simple obesity n.r. \pm n.r. (18–45)	3 mo	CV9, CV7, ST25, ST40	(A) ACE	(B) EA	(A) 60 (B) 30	Total effective rate	RR, 1.09 [0.97, 1.24], <i>P</i> = .16	n.r.
										(Continued)

Zhao et al.	•	Medicine (2022) 101:51

Table 1

Wang (2006) China ^{r2} S	Simula ohesity			Duration Acupoints of ACE	intervention	intervention	Sample size	measure	Effects estimates	Adverse events
		(A) 37.3 ± 3.67 (15–68) (B) 38.7 ± 4.2 (19–65)	8 WK	CV12, CV6, ST21, ST25, BL17, EX-B3, ST40	(A) ACE	(B) MA	(A) 31 (B) 26	Total effective rate BMI BW BW HC HC FBG FINS IR TG TC LDL-C HDL-C	RR, 1.01 [0.88, 1.17], $P = .86$ MD, 1.06 [-1.11 , 3.23], $P = .34$ MD, 0.77 [-3.14 , 4.69], $P = .70$ MD, 0.12 [-4.93 , 5.17], $P = .96$ MD, -0.33 [-6.02 , 5.36], $P = .16$ MD, -0.21 [-0.50 , 0.08], $P = .16$ MD, -0.71 [-1.99 , 1.17], $P = .61$ MD, -0.71 [-2.61 , 1.19], $P = .46$ MD, -0.71 [-2.61 , 1.19], $P = .46$ MD, -0.71 [-0.22 , 0.33], $P = .16$ MD, -0.07 [-0.17 , 0.03], $P = .16$ MD, 0.06 [-0.22 , 0.34], $P = .68$ MD, 0.07 [-0.07 , 0.001, $P = .17$	и и
Wang (2006) China ^[73] Simple obesity n.r. \pm n.r. (n.r.)	Simple obesity	ח.ר. ± ח.ר. (ח.ר.)	8 wk	ST37, ST40, SP6, SP4, ST34, ST25, RI 20, RI 21, RI 25,	(A) ACE	(B) MA	(A) 30	Total effective rate	RR, 1.27 [1.01, 1.61], $P = .05$	n.r.
Wang (2008) China ^[74]	Simple obesity and obesity	(A) 28.54 ± 5.8 (n.r.) (B) 30.09 ± 6.97 (n.r.)	3 mo	CV12, ST25, CV6, ST37	(A) ACE	(B) EA	(A) 30 (B) 30 (B)	Total effective rate BMI BW WC WC HC FINS TC TC LDL LDL LDL	RR, 1.00 [0.87, 1.14], $P = 1.00$ MD, 0.88 [-0.89 , 2.65], $P = .33$ MD, 0.88 [-0.89], 2.520, 3.42], $P = .25$ MD, -0.89 [-5.20 , 3.42], $P = .26$ MD, 1.26 [-2.48 , 5.00], $P = .51$ MD, 0.21 [-0.27 , 0.69], $P = .51$ MD, -0.15 [-0.25 , 0.06], $P = .11$ MD, -0.25 [-0.56 , 0.06], $P = .11$ MD, -0.08 [-0.34 , 0.18], $P = .96$ MD, -0.08 [-0.34 , 0.18], $P = .96$ MD, -0.03 [-0.37 , 0.31], $P = .86$	Syncope
Wang (2011) China ^[75] Simple obesity (A) 31.38 \pm 6.71 (18-55) (B) 32.63 \pm 6.78 (B) 32.63 \pm 6.78 (16-54)	Simple obesity	(A) 31.38 ± 6.71 (A) $218-55$ (B) 32.63 ± 6.78 (16-54)	2 mo	ST25, CV1 2, CV4, BL25, BL20, ST24, ST26, CV9, CV7	(A) ACE plus EA	(B) EA	(A) 40 (B) 40	FBG FBG FINS HOMA-IR	$\begin{array}{l} \text{WD}_{1} = -0.50 & \left[-0.34, -0.54 \right] \\ \text{WD}_{2} = -0.16 & \left[-0.31, -0.01 \right], P = .04 \\ \text{MD}_{1} = 0.08 & \left[-0.14, 0.30 \right], P = .47 \\ \text{MD}_{1} = -0.72 & \left[-1.58, 0.14 \right], P = .10 \\ \text{MD}_{1} = -0.05 & \left[-0.10, -0.00 \right], P = .03 \end{array}$	u.r.
Wang (2013) China ^[76] S	Simple obesity	(A) 31.20 ± 1.34 (20-46) (B) 31.20 ± 1.04 (21-52)	6 wk	CV12, ST25, CV4, ST28, GB26	(A) ACE	(B) MA	(A) 30 (B) 30	Total effective rate BMI BW WC	RR, 1.21 [0.86, 1.69], $P = .27$ MD, -1.07 [-1.35 , -0.79], $P < .00001$ MD, -2.49 [-3.95 , -1.03], $P = .0008$ MD, -0.72 [-1.66 , 0.22], $P = .13$	Contusion, allergy, nodule formation
Wang (2013) China ^[77]	Simple obesity	(A) 41.5 ± n.r. (23–60) (A) 40.5 ± n.r. (20. 61)	2 mo	ST21, ST28, ST36, CV9, ST27, GP26, achi acumunctura point	(A) ACE plus AA	(B) AA	(A) 30	Total effective rate	RR, 1.27 [1.01, 1.61], <i>P</i> = .05	n.r.
Wen (2013) China ^[78] S	Simple obesity	(10–01) ב ווו: (ב0–01) ח.ר. ± ח.ר. (ח.ר.)	45 d	CV12, ST25, CV4, ST28, SP15, ST36, ST37, SP10, SP6, ST40, SPa	(A) ACE plus MA	(B) MA	(b) 50 (A) 50 (B) 50	Total effective rate	RR, 1.29 [1.00, 1.67], <i>P</i> = .05	n.r.
Wu (2017) China ^[79] S	Simple obesity	Simple obesity (A) 41.06 \pm 12.05 (21-64) (B) 43.27 \pm 11.0 (24-54)	12 wk	CV12, ST25, SP15, CV4, CV6, ST28, ST29, BL18, BL19, BL20, BL21, BL22, BL23, BL25, GB26	(A) ACE	(B) EA	(A) 76 (B) 73	Total effective rate BMI	RR, 1.07 [0.93, 1.24], <i>P</i> = .32 MD, –0.52 [–2.51, 1.47], <i>P</i> = .61	J.L.

(Continued)										
First author (year) Country	Type of obesity	Age (mean ± SD) (range)	Duration	Duration Acupoints of ACE	Experimental intervention	Control intervention	Sample size	Outcome measure	Effects estimates	Adverse events
Xu (2015) China ⁽⁸⁰⁾	Simple obesity	(A) 33.26 ± 8.82 (19-47) (B) 33.66 ± 9.28 (19-47)	6 wk	CV12, GB26, ST36	(A) ACE plus EA	(B) EA	(A) 31 (B) 29	Total effective rate BMI BW WC HC RFP	RR, 1.01 [0.81, 1.27], $P = .91$ MD, -0.12 [-1.18 , 0.94], $P = .82$ MD, 1.05 [-0.38 , 2.48], $P = .15$ MD, 0.60 [-0.72 , 1.92], $P = .37$ MD, -0.18 [-1.40 , 1.04], $P = .77$ MD, -0.218 [-1.40 , 1.04], $P = .77$	u.r.
Xue (2017) China ^[81]	Obesity	(A) n.r. ± n.r. (29–48) (B) n.r. ± n.r. (28–49)	10 wk	ST25, SP9, ST40, ST36, TE6, CV12, SP6, BL20, BL21	(A) ACE plus Chuna	(B) Chuna	(A) 25 (B) 25	<i>l</i> e rate	$ \begin{array}{c} \text{WR}_{1} 1.28 \left[0.98, 1.67 \right] , P = .08 \\ \text{MD}_{1} - 1.79 \left[-1.94, -1.64 \right], P = .08 \\ \text{MD}_{2} - 1.29 \left[-1.34, -1.64 \right], P = .0001 \\ \text{MD}_{1} - 7.92 \left[-13.74, -2.10 \right], P = .008 \\ \text{MD}_{1} - 5.04 \left[-8.19, -1.89 \right], P = .002 \\ \text{MD}_{1} - 0.74 \left[-0.87 \right] - 0.61 \right], P = .0001 \\ \text{MD}_{1} - 0.31 \left[-0.41, -0.21 \right], P < .00001 \\ \text{MD}_{1} - 0.31 \left[-0.41, -0.21 \right], P < .00001 \\ \text{MD}_{1} - 0.40 \left[-0.65 \right], P < .00001 \\ \text{MD}_{1} - 0.40 \left[-0.65 \right] - 0.427 P < .00001 \\ \text{MD}_{1} - 0.40 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.421 \left[-0.221 \right], P < .00001 \\ \text{MD}_{2} - 0.421 \left[-0.221 \right], P < .00001 \\ \text{MD}_{2} - 0.421 \left[-0.221 \right], P < .00001 \\ \text{MD}_{2} - 0.40 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.421 \left[-0.221 \right], P < .00001 \\ \text{MD}_{2} - 0.40 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.40 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.40 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.40 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.40 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.40 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.41 \left[-0.22 \right], P < .00001 \\ \text{MD}_{2} - 0.41 \left[-0.22 \right], P < .00001 \\ \text{MD}_{2} - 0.41 \left[-0.22 \right], P < .00001 \\ \text{MD}_{2} - 0.41 \left[-0.22 \right], P < .00001 \\ \text{MD}_{2} - 0.40 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.40 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.40 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.40 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ \text{MD}_{2} - 0.60 \left[-0.65 \right], P < .00001 \\ $	J.F.
Yan (2015) China ^{laz}	Simple obesity	(A) 32.35 ± 11.93 (n.r.) (B) 33.74 ± 9.44 (n.r.)	40 d	CV12, CV9, ST25, GB26, TE6, L111, SP9, ST36, ST40, SP6, SP15	(A) ACE	(B) EA	(A) 27 (B) 26	Total effective rate BMI BW WC	$\begin{array}{c} \text{MR}, 1.00 \ (2.86, 1.17], P = .97 \\ \text{MD}, 0.29 \ [-1.60, 2.18], P = .97 \\ \text{MD}, 0.29 \ [-1.60, 2.18], P = .76 \\ \text{MD}, -0.61 \ [-6.43, 5.51], P = .84 \\ \text{MD}, -0.10 \ [-3.55, 3.55], P = .95 \\ \text{MD} \end{array}$	IJ.ſ
Yang (2014) China ⁽⁸³⁾	Simple obesity	(Å) 32.35 ± 11.83 (n.r.) (B) 34.74 ± 9.54 (n.r.)	1 mo	CV12, CV9, ST25, SP15, GB26, ST28, L111, TE6, SP9, ST36, ST40, SP6	(A) ACE	(B) EA	(A) 29 (B) 28	Total effective rate BMI BW BFP	$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \end{array} \\ \end{array} \end{array} \\ \begin{array}{c} \begin{array}{c} \end{array} \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \end{array} \\ \end{array} \end{array} \\ \begin{array}{c} \end{array} \end{array} \\ \end{array} \end{array} \\ \end{array} \end{array} \\ \begin{array}{c} \end{array} \end{array} \\ \end{array} \\ \end{array} \end{array} \\ \end{array} \\ \end{array} \end{array} \\ \\ \end{array} \\ \\ \end{array} \\ \end{array} \\ \\ \end{array} \\ \end{array} \\ \\ \end{array} \\ \\ \end{array} \\ \end{array} \\ \\ \\ \end{array} \\ \\ \end{array} \\ \\ \\ \end{array} \\ \\ \\ \\ \end{array} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \end{array} \\$	n.r.
Yin (2013) China ^[84]	Simple obesity	(A) 68.5 ± n.r. (61−76) (B) 65.8 ± n.r. (60−74)	3 mo	CV12, ST25, SP15, Ll11, TE6, ST44. ST40, ST37, SP9	(A) ACE	(B) MA	(A) 30 (B) 28	Total effective rate	RR, 1.40 [0.91, 2.15], $P = .12$	n.r.
You (2009) China ^{leg}	Simple obesity		8 WK	CV12, CV9, ST25, ST21, CV6, ST40	(A) AGE	(B) MA	(A) 30 (B) 30 (B) 30	Total effective rate BMI BW WC WC HC TC TC TC TC	RR, 0.96 [0.78, 1.19], $P = .72$ MD, 0.93 [-0.82 , 2.68], $P = .30$ MD, -3.55 [-10.68 , 3.58], $P = .33$ MD, -1.06 [-5.62 , 3.50], $P = .65$ MD, -0.13 [-3.89 , 3.63], $P = .95$ MD, 0.00 [-0.13 [-3.89 , 3.63], $P = .95$ MD, 0.00 [-0.18 , 0.20], $P = .92$ MD, -0.02 [-0.23 , 0.19], $P = .92$ MD, -0.02 [-0.22 , 0.10], $P = .92$ MD, 0.07 [-0.20 (-0.23 , 0.19], $P = .85$	n.r.
Zhang (2011) China ^[86]	Simple obesity	Simple obesity (A) 31.29 ± 9.92 (19-51) (B) 29.47 ± 8.85 (n.r.)	4 mo	 (1) ST25, GB26, ST28, CV12, CV4, ST40 (2) BL20, BL21, BL25, BL22, ST37 	(A) ACE	(B) EA	(A) 30 (B) 30	Total effective rate BMI BW	$\begin{array}{c} \text{MR}_{1} 1.12 & \text{CO}_{1} (5.13) \\ \text{MR}_{1} 1.12 & \text{CO}_{2} (5.13) \\ \text{MD}_{1} -1.94 & [-4.00, 0.12] \\ \text{MD}_{1} -0.27 & [-4.18, 3.64] \\ \text{MD}_{1} -0.27 & [-2.84, 17] \\ \text{MD}_{1} 0.68 & -2.86 \\ \text{MD}_{1} -2.28 & 4.77 \\ \text{MD}_{1} -2.86 & -2.71 \\ \text{MD}_{2} -2.86 & -2.71 \\ \text{MD}_{1} -2.71 & -2.71 \\ \text{MD}_{2} -2.86 & -2.71 \\ \text{MD}_{1} -2.71 & -2.71 \\ \text{MD}_{2} -2.71$	IJ.ſ.
Zhang (2016) China ^{I87}	Simple obesity	(A) 38.93 ± 14.46 (n.r.) (B) 41.73 ± 14.42 (n.r.)	8 wk	CV12, GB26, ST36	(A) ACE	(B) EA	(A) 30 (B) 30	Total effective rate BMI BW WHR BFP	$ \begin{array}{l} \text{MD}, -0.01 \left[\begin{array}{c} 1.000 \\ 1.000 \left[0.022 \right] , 1.32 \right], P = .74 \\ \text{MD}, -0.38 \left[-0.97 \right] , 0.21 \right], P = .21 \\ \text{MD}, -2.00 \left[-5.91 \right] , 1.91 \right], P = .32 \\ \text{MD}, 0.00 \left[-0.03 \right] , 0.03 \right], P = 1.00 \\ \text{MD}, -0.01 \left[-1.21 \right] , 1.19 \right], P = .99 \\ \end{array} $	Pain, irritation

First author (year) Country	Type of obesity	Age (mean ± SD) (range)	Duration	Duration Acupoints of ACE	Experimental intervention	Control intervention	Sample size	Outcome measure	Effects estimates	Adverse events
Zhang (2017) China ^{I88}	Simple obesity	(A) 45.83 \pm 11.90 (18-55) (B) 42.75 \pm 12.21 (18-55) (18-55)	9 9 9	CV12, CV6, CV9, ST36, ST40, SP9, SP6, BL20, BL21, JiaJi point	(A)ACE	(B) MA	(A) 33 (B) 33	Total effective rate BMI BW WC HC BFP WHR TC TG LDL-C	RR, 1.20 [0.96, 1.50], $P = .11$ MD, -0.73 [-2.11 , 0.65], $P = .30$ MD, -3.30 [-4.74 , -1.86], $P < .00001$ MD, -3.26 [-5.80 , -0.72], $P = .01$ MD, -2.12 [-5.60 , 1.36], $P = .23$ MD, -1.62 [-2.65 , -0.59], $P = .23$ MD, -0.31 [-0.79 , 0.18], $P = .21$ MD, -0.31 [-0.79 , 0.18], $P = .21$ MD, -0.18 [-0.37 , 0.01], $P = .05$ MD, -0.20 [-0.40 , -0.00], $P = .05$	u.r.
Zhang (2017) China ^{leaj}	Simple obesity	(A) 61.35 ± 3.11 (n.r.) (B) 61.26 ± 3.07 (n.r.)	е Ю	CV12, ST25, CV6, ST37	(A) AGE	(B) MA	(A) 40 (B) 40	HDL-C Total effective rate BMI BW WC WC HC TC TC TC	MD, 0.12 [0.00, 0.24], $P = .05$ RR, 1.22 [1.04, 1.43], $P = .02$ MD, -0.69 [-4.36 , 2.98], $P = .71$ MD, -5.45 [-10.34 , -0.56], $P = .03$ MD, -4.23 [-6.86 , -1.60], $P = .002$ MD, -0.14 [-3.18 , 2.90], $P = .93$ MD, -0.014 [-0.13 , 0.17], $P = .79$ MD, 0.02 [-0.13 , 0.17], $P = .79$ MD, 0.06 [-0.06 , 0.18], $P = .31$	
Zheng (2013) China ⁽⁹⁰⁾	Simple obesity	Simple obesity n.r. ± n.r. (n.r.)	8 WK	CV12, ST25, CV6, GB26, LI11, ST36, SP6	(A) ACE	(B) MA	(A) 30 (B) 30	Total effective rate BMI BM BFP WHR BFP GLU INS GLU TC	$\begin{array}{l} \mbox{WD}, -0.03 \ [-0.13], \ r=.72 \\ \mbox{RR}, 1.05 \ [0.74, 1.48], \ P=.78 \\ \mbox{MD}, 0.22 \ [-0.23, 0.67], \ P=.34 \\ \mbox{MD}, -0.37 \ [-2.71, 1.97], \ P=.76 \\ \mbox{MD}, -0.79 \ [-2.51, 1.97], \ P=.76 \\ \mbox{MD}, 0.26 \ [-2.10, 2.62], \ P=.35 \\ \mbox{MD}, 0.26 \ [-2.51, -0.05], \ P=.35 \\ \mbox{MD}, 0.26 \ [-2.51, -0.05], \ P=.35 \\ \mbox{MD}, 0.26 \ [-0.51, 0.51], \ P=.100 \\ \mbox{MD}, 0.06 \ [-0.50, 0.51], \ P=.100 \\ \mbox{MD}, 0.08 \ [-0.21, 0.31], \ P=.58 \\ \mbox{MD}, 0.08 \ [-0.21, 0.37], \ P=.58 \\ \mbox{MD}, 0.08 \ $	ч. С
Zhou (2016) China ^[91]	Simple obesity and lower body obesity	34.56 ± 4.24 (22−51)	12 d	ST36, GB26, SP10, CV9, CV7, ST36, LI11	(A) ACE	(B) EA	(A) 40 (B) 40	Total effective rate BFP	wu,0.02 (0.20, 0.10), <i>P</i> = .33 RR, 1.11 [0.98, 1.27], <i>P</i> = .10 MD, -5.37 [-7.57, -3.17], <i>P</i> < .00001	n.r.
Zhou (2020) China ^{Irs}	Simple obesity n.r. (20–45)	n.r. (20–45)	2 mo	CV12, CV9, ST25, SP15, ST28, L111, TE6, SP9, ST36, ST40, SP6	(A) ACE	(B) EA	(A) 45 (B) 45	Total effective rate BMI BW WC BFP	RR, 1.03 [0.88, 1.20], <i>P</i> = .75 MD, 0.47 [-0.36, 1.30], <i>P</i> = .52 MD, -1.24 [-5.58, 3.10], <i>P</i> = .58 MD, -3.12 [-6.18, -0.06], <i>P</i> = .05 MD, -0.67 [-4.46, 3.12], <i>P</i> = .73	г.

First author (year) Country	Type of obesity	Age (mean ± SD) (range)	Duration	Duration Acupoints of ACE	Experimental Control interventi	Experimental Control intervention Sample size	Sample size	Outcome measure	Effects estimates	Adverse events
Zong (2009) China ¹⁹²¹	Simple obesity	Zong (2009) China ^{la21} Simple obesity (A) 29.54 ± 5.80 (n.r.) (B) 30.09 ± 6.97 (n.r.)	3 mg	CV12, ST25, CV6, ST37	(A) ACE plus EA	(B) EA	(A) 50 (B) 50	Total effective rate BMI BW BW WC WC HC FINS TC TC TC TC TC TC TC TC TC TC TC TC TC	RR, 1.09 [0.98, 1.20], $P = .10$ MD, -3.14 [-4.43, -1.85], $P < .00001$ MD, -7.07 [-11.45, -2.69], $P = .002$ MD, -5.79 [-9.15, -2.43], $P = .007$ MD, -1.59 [-4.48, 1.31], $P = .28$ MD, 0.28 [-1.50, 2.06], $P = .76$ MD, 0.28 [-1.50, 2.06], $P = .76$ MD, 0.28 [-1.50, 2.06], $P = .76$ MD, 0.28 [-0.57, 0.05], $P = .01$ MD, -0.31 [-0.56, -0.06], $P = .01$ MD, 0.10 [-0.00, 0.20], $P = .03$ MD, 0.10 [-0.00, 0.20], $P = .03$ MD, -0.04 [-0.28, 0.20], $P = .03$	Syncope

= low-density lipoprotein cholesterol, LH = luteinizing hormone, MA = manual acupuncture, MD = mean difference, nr. = not reported, RR = risk ratio, T = total cholesterol, TG = trighceride, TM-x = tumor necrosis factor alpha, WC = waist circumference,

not reach statistical significance, with low heterogeneity (n = 623, MD = -0.01 [-0.02, 0.01]; P = .29, $I^2 = 36\%$).

3.3.2.7. *BFP.* Six studies^[15,50,54,83,87,91] compared ACE with EA in terms of BFP. The pooled result indicated that ACE was more effective than EA, although there was no statistically significant difference between the two treatments (n = 399, MD = -1.53 [-3.17, 0.11]; *P* = .07, *I*² = 76%).

3.3.3. ACE plus MA versus MA.

3.3.3.1. Total effective rate. The outcomes for ACE plus MA versus MA were reported in six studies.^[26,31,38,42,50,78] The pooled data favored ACE plus MA (n = 574, RR = 1.15 [1.02, 1.29]; P = .02, $I^2 = 60\%$).

3.3.3.2. *BMI*. Two trials^[42,50] studied the effect of ACE plus MA on BMI. In all, 198 participants showed an improvement in this outcome; however, the results showed boundary differences between ACE plus MA and MA (n = 198, MD = 0.70 [-0.79, 2.19]; P = .35, $I^2 = 75\%$).

3.3.3. *BW.* Two studies^[31,42] reported BW data for ACE plus MA. Moreover, meta-analyses revealed that ACE plus MA was more beneficial for losing weight than MA (n = 120, MD = -2.80 [-5.34, -0.26]; *P* = .03, *I*² = 0).

3.3.3.4. WC. Only one study^[42] assessed WC data, and it found a borderline difference between the two groups (MD = -2.33 [-6.31, 1.65]; *P* = .25).

3.3.3.5. *HC*. Only one study^[42] assessed HC data; combination therapy had no significant effect on HC (n = 60, MD = -2.26 [-5.16, 0.64]; *P* = .13).

3.3.3.6. *WHR*. Two studies^[38,50] reported that WHR was better in the ACE plus MA group than in the MA group, although there was no statistically significant difference (n = 274, SMD = -0.79 [-1.96, 0.38], *P* = .19).

3.3.3.7. *BFP.* Two studies,^[38,50] with 274 participants, were included in this group. There were borderline differences between the groups (MD = -2.49 [-6.23, 1.26]; *P* = .19, *I*² = 95%).

3.3.4. ACE plus EA versus EA.

3.3.4.1. Total effective rate. Nine studies^[23,24,33,47,54,67,70,80,92] compared the total effective rate of ACE plus EA to that of EA. The pooled analysis showed that ACE plus EA was superior to EA alone (n = 795, RR = 1.05 [1.00, 1.11]; P = .05, $I^2 = 29\%$).


3.3.4.2. *BMI.* Seven trials^[23,24,47,54,70,80,92] involving a total of 655 participants reported BMI as an outcome. Significant heterogeneity was observed between the studies ($I^2 = 84\%$). Subgroup analyses of similar age groups (20s) between the treatment and comparison groups were performed. Three compared the effect of ACE plus EA with EA alone; there were significant differences between the groups, with ACE plus EA being favored (n = 360, MD = -3.12 [-2.16, -2.39]; *P* < .00001, $I^2 = 0$) (Fig. 4A).


3.3.4.3. *BW.* We analyzed the data of five studies^[23,47,70,80,92] that reported on BW data. Our pooled analysis showed borderline differences between the two groups (MD = -3.16 [-7.73, 1.41]; *P* = .18, *I*² = 91%).

3.3.4.4. WC. Six studies^[23,47,54,70,80,92] evaluated WC data. Significant heterogeneity was noticed among the studies ($I^2 = 86\%$). Therefore, we conducted subgroup analysis; combination therapy was more effective than EA alone in similar age range (20s) (n = 360, MD = -6.06 [-7.87, -4.25], *P* < .00001, $I^2 = 0$) (Fig. 4B).

= waist-to-hip ratio, WHtR = waist-height radio

WHR





3.3.4.5. *HC.* Five studies^[23,47,51,80,92] compared ACE plus EA with EA alone. The results showed that ACE plus EA led to a greater reduction in obesity than EA alone; however, the effect size was not statistically significant (n = 480, MD = -0.33 [-1.23, 0.58]; P = .47, $I^2 = 0$).

3.3.4.6. WHR. Three studies^[47,54,70] reported a reduction in WHR with ACE plus EA compared with EA. The combined result showed that combination therapy reduced the WHR, but the effect was not statistically significant (n = 325, MD = -0.05 [-0.11, 0.00]; P = .07, $I^2 = 76\%$).

3.3.4.7. *BFP*. Two studies^[54,80] reported on BFP. There was no significant difference in BFP effect size (n = 120, MD = -1.28 [-3.53, 0.97]; P = .26, $I^2 = 86\%$).

3.3.5. ACE plus AA versus AA.

3.3.5.1. Total effective rate. Two studies^[35,77] that examined the total effective rate of treating obesity with ACE plus AA versus AA were analyzed using a random-effects model; the pooled result favored ACE plus AA (n = 120, RR = 1.30 [1.09, 1.56]; P = .004, $I^2 = 0$).

3.3.5.2. *BMI.* Only one study^[35] reported BMI data pertaining to ACE plus AA versus AA alone. A significant difference was observed between the two therapies (n = 60, MD = -1.70 [-2.74, -0.66]; *P* = .0001).

3.3.5.3. *BW.* Only one study^[35] reported BW data. However, there was a borderline difference between the two groups (n = 60, MD = -3.76 [-9.89, 2.37]; *P* = .23).

3.3.5.4. WC. Only one study^[35] assessed WC data; there was a significant difference between the two methods (n = 60, MD = -3.70 [-6.51, -0.89]; P = .010).

3.3.5.5. *HC.* Only one study^[35] compared ACE plus AA and AA alone; there was a significant difference between the treatment and control groups (n = 60, MD = -2.23 [-5.09, 0.63]; *P* = .13).

3.3.6. ACE plus cupping therapy versus cupping therapy.

3.3.6.1. Total effective rate. One study^[55] reported a significant improvement in obesity with ACE plus cupping compared with cupping alone (n = 100, RR = 1.13 [1.08, 1.60]; P = .007).

3.3.7. ACE plus CMT versus CMT.

3.3.7.1. Total effective rate. Three studies^[66,68,81] evaluated ACE plus CMT versus CMT for the treatment of obesity. The results showed that ACE plus CMT was better than CMT alone (n = 430, RR = 1.42 [1.26, 1.60]; P < .00001, $I^2 = 0$).

3.3.7.2. *BMI*. Three studies^[66,68,81] reported BMI data; ACE plus CMT was better than CMT alone (n = 430, MD = -2.57 [-3.29, -1.85]; *P* < .00001, *I*² = 98%).

3.3.7.3. *BW.* We pooled data from three studies^[66,68,81] that reported BW data. The meta-analysis indicated that ACE plus CMT had a better effect than CMT (MD = -9.19 [-11.28, -7.10]; *P* < .00001, *I*² = 0).

3.3.7.4. WC. The pooled data of three studies^[66,68,81] showed that ACE plus CMT was beneficial for WC (n = 430, MD = -5.40 [-7.16, -3.64]; *P* < .00001, *I*² = 26%).

3.3.7.5. *WHR.* Only one study^[68] evaluated the effect of ACE plus CMT on WHR, and it found a significant difference between the two groups (n = 300, MD = -0.11 [-0.16, -0.06]; *P* < .00001).

3.3.8. Secondary outcomes. Our meta-analyses revealed that ACE was more beneficial for the recovery of metabolic markers. ACE had a beneficial effect on TC and triglyceride levels (MD $= -0.20 [-0.39, -0.01]; P = .04, I^2 = 95\%; MD = -0.08 [-0.16]$ 0.00]; P = .05, $I^2 = 68\%$ respectively.) When we compared ACE with EA, TC levels were significantly different between the two groups (n = 360, MD = -0.16 [-0.29, -0.03]; P = .02, $I^2 = 0$), whereas triglyceride levels were not significantly different (n = $371, MD = -0.03 [-0.14, 0.08]; P = .55, I^2 = 0)$. Moreover, when we compared ACE plus MA to MA, the combination therapy was more effective than MA alone in improving triglyceride levels. However, there was no statistical difference (n = 274, MD = -0.45 [-1.59, 0.69]; P = .44, $I^2 = 74\%$). On analyzing the effect of ACE plus EA and EA, similar effects on TC and triglyceride levels were observed (n = 261, MD = -0.16 [-0.33, 0.01]; P = .07, $I^2 = 0$; n = 341, MD = -0.09 [-0.23, 0.06]; P = $.24, I^2 = 65\%$, respectively). Lastly, when we compared ACE plus CMT and CMT, the combination therapy was more effective than CMT (n = 430, MD = -0.65 [-0.72, -0.58]; P < .00001, I² = 22%; n = 430, [-0.34, -0.28]; P < .00001, I² = 0, respectively).

3.3.9. Adverse events. Thirteen RCTs reported adverse events.^[23,25,40,42,43,55,63,66,68,74,76,87,92] The main common adverse reactions were nodule formation, contusion, syncope, and fever. Fatigue, vomiting, trauma, blister, scleroma, allergy, pain, and irritation were other adverse events. However, no serious adverse events were reported in the studies.

3.3.10. *Publication bias.* The funnel plots prepared using RevMan software are presented in the Supplemental Digital Content 4 and 5, http://links.lww.com/MD/H825. The overall efficacy was symmetrical and demonstrated no significant publication bias.

Α		_								
	AC		MA		M/- !!		Risk Ratio		Risk Ratio	
Study or Subgroup	Event				Weigh		. Random, 95% CI	M-H,	Random, 95% CI	
Chen(2007)	36		35	40	4.59		1.03 [0.88, 1.20]			
Chen(2016)	45 34		39	47	4.99 2.99		1.15 [1.00, 1.33]			
Chen(2019)	14		24 13	35 30	0.79		1.42 [1.12, 1.79]			
Deng(2014) Ding(2006)	59		54	50 64	5.39		1.08 [0.62, 1.89] 1.08 [0.94, 1.23]		+-	
Ge(2015)	37		36	40	5.19		1.03 [0.90, 1.18]		+-	
Guo(2014)	32		30	34	4.49		1.04 [0.88, 1.22]		- - -	
Huang(2019)	30		20	33	2.19		1.50 [1.12, 2.02]			
Li(2005)	28		20	21	5.19		0.98 [0.86, 1.12]		+	
Li(2007)	33		34	36	5.49		0.97 [0.86, 1.10]		-	
Li(2009)	63		62	68	5.89		0.96 [0.86, 1.08]		+	
Li(2012)	43		36	45	4.49		1.19 [1.02, 1.40]			
Li(2020)	45		33	49	3.29		1.36 [1.10, 1.69]			
Liu(2007)	29		28	32	4.19		1.04 [0.87, 1.23]			
Liu(2009)	28		24	30	3.49		1.17 [0.95, 1.43]		+	
Luo(2016)	29		22	30	3.09		1.32 [1.05, 1.65]			
Mai(2013)	31		23	32	3.09		1.35 [1.08, 1.69]			
Meng(2005)	37		33	48	2.79		1.12 [0.88, 1.43]		+	
Qiao(2016)	28		22	30	2.89		1.27 [1.01, 1.61]			
Ren(2009)	12		8	22	0.59		1.50 [0.77, 2.94]			
Sun(2020)	25		21	25	3.89		1.19 [0.99, 1.43]			
Wang(2006)	29		24	26	4.9		1.01 [0.88, 1.17]		+	
Wang(2006)(1)	28		22	30	2.89		1.27 [1.01, 1.61]			
Wang(2013)	23		19	30	1.79		1.21 [0.86, 1.69]		+	
Yin(2013)	21		15	30	1.19		1.40 [0.91, 2.15]		+	
You(2009)	25		26	30	3.29		0.96 [0.78, 1.19]		-	
Zhang(2017)	30		25	33	3.19		1.20 [0.96, 1.50]		—	
Zhang(2017)(1)	39	9 40	32	40	4.49		1.22 [1.04, 1.43]		_ _ _	
Zheng(2013)	21		20	30	1.69		1.05 [0.74, 1.48]		_ 	
Total (95% CI)		1060		1040	100.09	%	1.12 [1.07, 1.18]		•	
Total events	934	1	800							
Heterogeneity: Tau ² =	= 0.01; Ch	i ² = 50.7	7, df = 28	B (P = 0)	.005); l ^a	² = 45%	-	0.5 0.7	7 1 1.5 2	
Test for overall effect:	Z = 4.74	(P < 0.0	0001)					0.5 0.	MA ACE	
									WA AOL	
В	A	CE		MA			Mean Difference	м	ean Difference	
Study or Subgroup			al Mean		Total V	Neight	IV. Random, 95% CI		Random, 95% CI	
Guo(2011)			35 27.38	5.89	34	5.6%	-2.39 [-5.20, 0.42]			
Li(2007)	26.26 4	.12	36 27.31	4.78	36	10.3%	-1.05 [-3.11, 1.01]		-	
Li(2020)	24.21 1	.93	0 05 07	0.04		04 00/				
			19 25.27	2.34	49	61.0%	-1.06 [-1.91, -0.21]		-	
Zhang(2017)	23.55 2		49 25.27 33 24.28			61.0% 23.1%	-1.06 [-1.91, -0.21] -0.73 [-2.11, 0.65]			
	23.55 2	.36	33 24.28		33	23.1%	-0.73 [-2.11, 0.65]		-	
Total (95% CI)		36	33 24.28 53	3.28	33 152 1			L	•	1
Total (95% Cl) Heterogeneity: Tau² =	0.00; Chi²	36 : 1! = 1.08, 0	33 24.28 53 df = 3 (P =	3.28	33 152 1	23.1%	-0.73 [-2.11, 0.65]	-20 -10	• • 0 10) 20
Total (95% CI)	0.00; Chi²	36 : 1! = 1.08, 0	33 24.28 53 df = 3 (P =	3.28	33 152 1	23.1%	-0.73 [-2.11, 0.65]	-20 -10	0 10) 20
Total (95% CI) Heterogeneity: Tau ² = (Test for overall effect: 2	0.00; Chi² Z = 3.12 (F	1:36 1: = 1.08, 0 P = 0.002	33 24.28 53 df = 3 (P =	3.28 0.78); I	33 152 1	23.1%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39]		ACE MA) 20
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2	0.00; Chi² Z = 3.12 (f At	1:36 = 1.08, (= 0.002 CE	33 24.28 53 3f = 3 (P = 2)	3.28 0.78); I MA	33 152 1 ² = 0%	23.1%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference	N	ACE MA) 20
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup	0.00; Chi² Z = 3.12 (I A(Mean	1:36 = 1.08, 0 = 0.002 CE SD To	33 24.28 53 55 (P = 2) tal_Mean	3.28 0.78); I MA SD	33 152 1 ² = 0% Total	23.1% 100.0% <u>Weight</u>	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random, 95% C	N	ACE MA) 20
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2007)	0.00; Chi ² Z = 3.12 (f <u>Mean</u> 60.35	18 = 1.08, 0 = 0.000 CE <u>SD To</u> 5.23	 33 24.28 53 df = 3 (P = 2) tal Mean 40 58.87 	3.28 0.78); I <u>MA</u> <u>SD</u> 6.36	33 152 1 ² = 0% <u>Total</u> 40	23.1% 100.0% <u>Weight</u> 6.1%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference <u>IV. Random, 95% C</u> 1.48 [-1.07, 4.03]	N	ACE MA) 20
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016)	0.00; Chi ² Z = 3.12 (F <u>Mean</u> 60.35 = 76.6	36 = 1.08, 0 P = 0.002 CE <u>SD To</u> 5.23 4.7	 33 24.28 53 34 = 3 (P = 2) 53 (P = 2) 54 = 10 (P = 2) 55 = 10 (P = 2) 56 = 10 (P = 2) 57 = 10 (P = 2) 58 = 10 (P = 2) 	3.28 0.78); I MA <u>SD</u> 6.36 5.9	33 152 1 ² = 0% <u>Total</u> 40 47	23.1% 100.0% Weight 6.1% 7.2%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44]	N	ACE MA) 20
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014)	0.00; Chi ² Z = 3.12 (f <u>Mean</u> 60.35 76.6 66.89	36 : = 1.08, (= 0.002 CE <u>SD To</u> 5.23 4.7 8.37	 33 24.28 53 34 = 3 (P = 2) 53 (P = 2) 54 = 10 (P = 2) 55 = 10 (P = 2) 56 = 10 (P = 2) 57 = 10 (P = 2) 58 = 10 (P = 2) 	3.28 0.78); I MA <u>SD</u> 6.36 5.9 6.62	33 152 1 ² = 0% <u>Total</u> 40 47 30	23.1% 100.0% Weight 6.1% 7.2% 3.7%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20]	N	ACE MA) 20
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015)	0.00; Chi ² Z = 3.12 (f <u>Mean</u> 60.35 76.6 66.89 79.34	36 : 19 = 1.08, (P = 0.002 CE <u>SD To</u> 5.23 4.7 8.37 9.41	 33 24.28 53 53 53 54.28 55 56 57 58.87 58.87 47 81.2 30 64.51 40 79.47 	3.28 0.78); I MA <u>SD</u> 6.36 5.9 6.62 8.42	33 152 1 ² = 0% Total 40 47 30 40	23.1% 100.0% Weight 6.1% 7.2% 3.7% 3.6%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference <u>IV. Random. 95% C</u> 1.48 [-1.07, 4.03] -4.60 [-6.76, -4.6.20] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78]	N	ACE MA) 20
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014)	0.00; Chi ² Z = 3.12 (F 60.35 76.6 66.89 79.34 66.39 10	36 : 19 = 1.08, (= 0.002 CE <u>SD To</u> 5.23 4.7 8.37 9.41 0.02	 33 24.28 53 53 53 54.28 55 56 57 58.87 58.87 47 81.2 30 64.51 40 79.47 	3.28 0.78); I MA <u>SD</u> 6.36 5.9 6.62 8.42	33 152 1 ² = 0% <u>Total</u> 40 47 30	23.1% 100.0% Weight 6.1% 7.2% 3.7%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. <u>95% C</u> 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.3.78] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21]	N	ACE MA) 20
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014)	0.00; Chi ² Z = 3.12 (f <u>Mean</u> 60.35 = 76.6 66.89 = 79.34 = 66.39 = 11 83.21 =	36 ; = 1.08, (= 0.002 CE <u>SD To</u> 5.23 4.7 8.37 9.41 0.02 3.08	 33 24.28 33 df = 3 (P = 2) tal Mean 40 58.87 47 81.2 30 64.51 40 79.47 35 69.23 	3.28 0.78); I MA 5D 6.36 5.9 6.62 8.42 11.33	33 152 1 ² = 0% Total 40 47 30 40 34	23.1% 100.0% Weight 6.1% 7.2% 3.7% 3.6% 2.4%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference <u>IV. Random. 95% C</u> 1.48 [-1.07, 4.03] -4.60 [-6.76, -4.6.20] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78]	N	ACE MA) 20
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2019) Huang(2020) Li(2005)	0.00; Chi ² Z = 3.12 (f <u>Mean</u> 60.35 = 76.6 66.89 = 66.39 = 10 83.21 = 68.93 = 68.93 = 77.02 =	36 14 = 1.08, (= 0.002 CE SD To 5.23 4.7 8.37 9.41 0.02 3.08 8.46 4.31	tal Mean 40 58.87 40 58.87 47 81.2 30 64.51 40 79.47 31 86.02 33 86.02 30 78.47	3.28 0.78); I MA 5.9 6.62 8.42 11.33 2.33 9.04 7.14	33 152 1 ² = 0% Total 40 47 30 40 34 33 39 21	23.1% 100.0% Weight 6.1% 7.2% 3.7% 3.6% 2.4% 9.9% 3.6% 4.3%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.42] 0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.77, 1.97]	N	ACE MA	0 20
Total (95% CI) Heterogeneity: Tau ² = / Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Gu(2014) Huang(2020) Li(2005) Li(2007)	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.89 79.34 66.39 11 83.21 68.93 77.02 67.9	36 14 = 1.08, (= 0.00) CE <u>SD To</u> 5.23 4.7 8.37 9.41 0.02 3.08 8.46 4.31 7.49	 24.28 33 24.28 34 35 35 36 36 47 310 48.47 49.47 30 49.47 30 49.47 30 49.47 30 49.47 30 49.47 30 49.47 310 49.47 49.47	3.28 0.78); I MA 5D 6.36 5.9 6.62 8.42 11.33 2.33 9.04 7.14 7.64	33 152 1 ² = 0% Total 40 47 30 40 34 33 39 21 36	23.1% 100.0% Weight 6.1% 7.2% 3.6% 2.4% 9.9% 3.6% 4.3% 4.2%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] 4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.84 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.87, 1.97] -3.10 [-6.59, 0.39]	N	ACE MA	0 20
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2019) Huang(2019) Li(2005) Li(2007) Li(2020)	0.00; Chi ² Z = 3.12 (f <u>Mean</u> 60.35 f 76.6 66.89 f 66.39 fl 83.21 f 68.93 f 77.02 f 68.93 f 77.02 f 69.59 f	.36 11 = 1.08, (= 0.002 CE SD To 5.23 4.7 8.37 9.41 0.02 3.08 8.46 4.31 7.49 5.54	33 24.28 53 if = 3 (P = if = 3 (P = 2) tal Mean 40 58.87 47 81.2 30 64.51 33 86.02 33 86.02 39 74.31 30 78.47 30 78.47 36 71 49 73.35	3.28 0.78); I MA 5D 6.36 5.9 6.62 8.42 11.33 2.33 9.04 7.14 7.64 5.5	33 152 1 ² = 0% Total 40 47 30 40 34 33 39 21 36 49	23.1% 100.0% Weight 6.1% 7.2% 3.6% 2.4% 9.9% 3.6% 4.3% 4.2% 7.1%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference <u>IV. Random. 95% C</u> 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.44] -5.38 [-9.27, -1.49] -1.45 [-4.87, 1.97] -3.10 [-6.59, 0.39] -3.76 [-5.95, -1.57]	N	ACE MA	0 20
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Li(2020) Liu(2007)	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.39 1 83.21 68.93 1 83.21 68.93 77.02 69.59 70.59 1	$\begin{array}{c} .36 \\ 1! \\ = 1.08, \\ 0 \\ = 0.00! \\ \hline \\ CE \\ SD To \\ 5.23 \\ 4.7 \\ 8.37 \\ 9.41 \\ 0.02 \\ 3.08 \\ 8.46 \\ 4.31 \\ 7.49 \\ 5.54 \\ 1.23 \end{array}$	 24.28 33 24.28 34 53 54 54 58 54 58 59 50 50 51 51	3.28 0.78); I MA 5.0 6.36 5.9 6.62 8.42 11.33 2.33 9.04 7.14 7.64 5.5 11.87	33 152 1 ² = 0% Total 40 47 30 40 34 33 39 21 36 49 32	23.1% 100.0% Weight 6.1% 7.2% 3.6% 2.4% 9.9% 3.6% 4.3% 4.3% 4.3% 7.1% 2.0%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference <u>IV. Random. 95% C</u> 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.87, 1.97] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00]	N	ACE MA) 20
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Liu(2007) Liu(2009)	0.00; Chi ² Z = 3.12 (f Mean 60.35 = 76.6 66.89 = 79.34 = 66.39 11 83.21 = 68.93 = 77.02 = 67.9 = 67.9 = 77.05 = 1 64.38 =	.36 19 = 1.08, 6 > = 0.000 CE 5.23 4.7 9.41 9.41 9.41 9.41 9.41 9.41 9.41 9.41	33 24.28 33 ff = 3 (P = 1f = 3 (P = 2) tal Mean 40 58.87 47 81.2 30 64.51 40 79.47 33 86.02 33 86.02 39 74.31 30 78.47 32 70.25 32 70.25 30 67.95	3.28 0.78); I MA <u>SD</u> 6.36 5.9 6.62 8.42 11.33 2.33 9.04 7.64 5.5 11.87 2.21	33 152 1 ² = 0% Total 40 47 30 40 47 30 40 47 30 40 47 30 40 47 30 40 47 30 40 47 30 40 47 30 40 40 40 40 47 30 40 40 40 40 40 40 40 40 40 4	23.1% 100.0% Weight 6.1% 7.2% 3.6% 3.6% 4.3% 4.3% 4.2% 7.1% 2.0% 10.1%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] 4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] 2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.87, 1.97] -3.10 [-6.59, 0.39] -3.76 [-5.95, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.83, -2.31]	N	ACE MA	0 20
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Huang(2020) Li(2007) Li(2007) Li(2009) Ren(2009)	0.00; Chi ² Z = 3.12 (f Mean 76.6 66.39 1 79.34 1 83.21 2 68.93 1 83.21 2 68.93 4 77.02 6 69.59 1 69.59 1 64.38 2 64.38 2	.36 1 = 1.08, 6 = 0.007 CE <u>SD To</u> 5.23 4.7 9.41 0.02 3.08 8.46 4.31 7.49 5.54 1.23 2.74 8.28	33 24.28 33 ff = 3 (P = 2) 1 1 40 58.87 1 40 58.87 81.2 30 64.51 1 40 79.47 81.2 33 86.02 33 30 74.31 30 30 78.47 71 49 73.35 32 70.25 30 67.95 22 65.61	3.28 0.78); I MA 6.36 5.9 6.62 8.42 11.33 2.33 9.04 7.14 7.64 5.5 11.87 2.21 7.22	33 152 1 2 = 0% Total 40 47 30 40 47 30 40 33 39 21 36 49 30 21	23.1% 100.0% Weight 6.1% 7.2% 3.7% 3.6% 2.4% 9.9% 3.6% 4.3% 4.2% 7.1% 2.0% 10.1% 2.8%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random, 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.87, 1.97] -3.10 [-6.59, 0.39] -3.76 [-5.95, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.83, -2.31] -1.56 [-6.20, 3.08]	N	ACE MA	0 20
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Liu(2007) Liu(2007) Liu(2009) Ren(2009) Wang(2006)	0.00; Chi ² Z = 3.12 (f Mean 60.35 5 76.6 66.89 1 79.34 5 66.39 11 83.21 5 68.93 1 68.93 1 67.9 5 67.9 5 67.9 5 70.59 1 64.38 5 64.05 4 78.34	.36 1 = 1.08, 6 = 0.002 CE <u>SD To</u> 5.23 4.7 9.41 0.02 3.08 8.46 4.31 7.49 5.54 1.23 2.74 8.28 7.41	33 24.28 33 def = 3 (P = 2) tal Mean 40 58.87 47 81.2 30 64.51 40 79.47 33 86.02 33 86.02 30 74.41 30 78.47 32 70.25 32 70.25 32 67.95 32 22 31 77.56	3.28 0.78); I MA 5.9 6.62 8.42 11.33 2.33 9.04 7.14 7.64 5.5 11.87 2.21 7.22 7.63	33 152 1 ² = 0% Total 40 47 30 40 40 40 40 40 34 33 39 21 36 49 32 30 21 26	23.1% 100.0% (6.1%) 7.2% 3.7% 3.6% 2.4% 9.9% 3.6% 4.2% 4.2% (10.1% 2.0% 10.1% 2.8% 3.6%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference <u>IV. Random. 95% C</u> 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] -2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.87, 19.7] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.83, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69]	N	ACE MA	0 20
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2007) Li(2007) Liu(2007) Liu(2009) Ren(2009) Wang(2006) Wang(2013)	0.00; Chi ² Z = 3.12 (f Mean 60.35 = 76.6 66.89 = 76.6 66.39 = 10 83.21 = 66.39 = 10 83.21 = 66.39 = 10 67.9 = 69.59 = 10 69.59 = 10 70.59 = 10 64.38 = 10 78.34 = 1078.34 = 10 78.34 = 10 78.34 = 1078.34 = 100 78.34 =	.36	33 24.28 33 aff = 3 (P = aff = 3 (P = 2) tal Mean 40 58.87 40 781.2 30 64.51 40 781.2 30 64.51 40 78.73 33 86.02 33 86.23 30 74.41 30 78.47 32 70.25 30 76.73 31 77.57 30 81.73	3.28 MA SD 6.36 5.9 6.62 8.42 11.33 2.33 9.04 7.14 5.5 11.87 7.221 7.63 3.01	33 152 1 ² = 0% Total 40 47 30 40 34 39 21 36 49 32 30 21 36 49 32 30 21 36 49 32 30 30 21 36 49 32 30 30 30 31 32 30 33 39 21 36 30 30 30 30 30 30 30 30 30 30	23.1% 100.0% 100.0% (0.1% 2.4% 9.9% 3.6% 2.4% 9.9% 4.3% 4.2% 7.1% 2.0% 10.1% 2.8% 3.6% 9.4%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] 4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] 2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -3.10 [-6.59, 0.39] -3.76 [-5.95, -1.63] -3.75 [-4.83, -2.31] -1.65 [-6.20, 3.08] 0.77 [-3.15, 4.69] -2.49 [-3.95, -1.03]	N	ACE MA	20
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Liu(2007) Liu(2007) Liu(2009) Ren(2009) Wang(2006)	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.89 4 79.34 66.39 18 33.21 5 67.9 69.59 5 70.59 1 64.38 5 64.38 7 70.22 67.9 5 70.59 1 64.38 7 70.4 5 70.5 1 64.38 7 70.4 7 70.5 1 70.5 1 67.9 7 70.5 10 1 70.5 10 1 70.5 10 1 70.5 10 1 70.5 10 1 70.5 10 1 70.5 10 1 70.5 10 1 1 70.5 10 1 70.5 10 1 70.5 10 1 70.5 10 10 10 10 10 10 10 10 10 10 10 10 10	.36 14 = 1.08, (> > = 0.007 > CE SD To 5.23 4.7 8.37 9.41 0.02 3.08 8.46 4.31 7.49 5.54 1.23 2.74 8.28 7.41 2.75 3.17	33 24.28 33 iff = 3 (P = iff = 3 (P = 2) tal Mean 40 58.87 47 81.2 30 64.51 33 86.02 39 74.31 30 78.47 30 78.47 30 70.25 30 67.95 30 67.95 31 77.57 30 81.73	3.28 MA SD 6.36 5.9 6.62 8.42 11.33 2.33 9.04 7.14 5.5 11.87 7.221 7.63 3.01	33 152 1 ² = 0% Total 40 47 30 40 40 40 40 40 34 33 39 21 36 49 32 30 21 26	23.1% 100.0% (6.1%) 7.2% 3.7% 3.6% 2.4% 9.9% 3.6% 4.2% 4.2% (10.1% 2.0% 10.1% 2.8% 3.6%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference <u>IV. Random. 95% C</u> 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] -2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.87, 19.7] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.83, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69]	N	ACE MA	0 20
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Li(2007) Li(2009) Ken(2009) Wang(2013) You(2009)	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.89 4 79.34 66.39 18 33.21 5 67.9 69.59 5 70.59 1 64.38 5 64.38 7 70.22 67.9 5 70.59 1 64.38 7 70.4 5 70.5 1 64.38 7 70.4 7 70.5 1 70.5 1 67.9 7 70.5 10 1 70.5 10 1 70.5 10 1 70.5 10 1 70.5 10 1 70.5 10 1 70.5 10 1 70.5 10 1 1 70.5 10 1 70.5 10 1 70.5 10 1 70.5 10 10 10 10 10 10 10 10 10 10 10 10 10	.:36 ; ; 11: = 1.08, 4 = 0.002 CE SD To S.23 3.07 4.37 4.4.7 3.37 7.49 4.31 1.23 5.54 4.31 1.23 7.49 4.31 1.27 5.54 3.37 7.49 5.54 3.37 7.41 5.54 5.57 5.57 5.57 5.77 5.77 5.77 5.77 5.74 5.77 5.77 5.77 5.77 5.77 5.77 5.74 5.77 5.77 5.77 5.77 5.74 5.77 5.77 5.77 5.77 5.77 5.74 5.77 5	33 24.28 33 if = 3 (P = if = 3 (P = 2) tal Mean 40 58.87 47 81.2 30 64.51 47 81.2 33 86.02 33 86.02 39 74.31 30 78.47 49 73.35 32 70.25 30 67.95 22 65.61 31 77.57 30 81.73 30 74.88	3.28 MA SD 6.36 6.62 8.42 11.33 2.33 9.04 7.14 7.55 11.87 2.21 7.22 7.63 3.01 14.95 3.47	33 152 1 ² = 0% Total 40 47 30 40 40 40 33 39 21 36 49 21 36 32 30 21 26 30 30 30	23.1% 100.0% 100.0% (0.1% 2.4% 9.9% 3.6% 4.3% 4.2% 7.1% 2.0% 10.1% 10.1% 2.8% 3.6% 9.4% 3.6% 9.4% 3.6%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.87, -1.49] -3.10 [-6.59, 0.39] -3.76 [-5.95, -1.57] 0.34 [-5.32, 6.00] 0.357 [-4.83, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69] 0.249 [-3.95, -1.03] -3.55 [-1.068, 3.58]	N	ACE MA) 20
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Li(2007) Liu(2007) Liu(2009) Ren(2009) Wang(2013) Yang(2017)	0.00; Chi ² Z = 3.12 (f Mean 60.35 = 76.6 66.89 = 76.6 66.39 = 10 83.21 = 68.93 68.93 = 77.02 67.9 = 77.02 67.9 = 77.05 69.59 = 77.05 69.59 = 77.05 69.59 = 77.05 70.59 = 1 64.38 = 64.05 79.24 = 77.33 79.24 = 77.33 79.24 = 77.33 71.37 = 77.35 71.37 = 77.55 71.33 = 17.55 71.33 = 17.55 71.37 = 77.55 71.33 = 17.55 71.33 = 17.55 71.37 = 77.55 71.35 = 77.55 71.55 = 77.55 71.55 = 77.55 = 7	.:36 ; ; 11: = 1.08, 4 = 0.002 CE SD To S.23 3.07 4.37 4.4.7 3.37 7.49 4.31 1.23 5.54 4.31 1.23 7.49 4.31 1.27 5.54 3.37 7.49 5.54 3.37 7.41 5.54 5.57 5.57 5.57 5.77 5.77 5.77 5.77 5.74 5.77 5.77 5.77 5.77 5.77 5.77 5.74 5.77 5.77 5.77 5.77 5.74 5.77 5.77 5.77 5.77 5.77 5.74 5.77 5	33 24.28 33 ff = 3 (P = 40 58.87 40 58.87 47 81.2 30 64.51 40 79.47 33 86.02 39 74.31 30 78.47 31 70.25 32 70.22 30 67.91 22 65.61 31 77.57 30 74.82 33 75.27	3.28 MA SD 6.36 6.62 8.42 11.33 2.33 9.04 7.14 7.55 11.87 2.21 7.22 7.63 3.01 14.95 3.47	33 152 1 ² = 0% Total 40 47 30 40 47 30 40 47 30 40 47 30 40 47 30 40 47 30 40 40 47 30 40 40 40 40 40 40 40 40 40 4	23.1% 100.0% 100.0% 6.1% 7.2% 3.6% 2.4% 9.9% 3.6% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3% 4.3	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference <u>IV. Random. 95% C</u> 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.47, 4.03] -4.60 [-6.76, -2.47, 4.03] -1.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -3.81 [-4.37, 1.97] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.83, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69] -2.45 [-10.68, 3.58] -3.30 [-4.74, -1.86]	N	ACE MA	0 20
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Li(2007) Liu(2007) Liu(2007) Liu(2009) Ren(2009) Wang(2013) You(2009) Zhang(2017) Zhang(2017)(1) Zheng(2013)	0.00; Chi ² Z = 3.12 (f Mean 60.35 = 76.6 66.89 = 76.6 66.39 = 10 83.21 = 68.93 68.93 = 77.02 67.9 = 77.02 67.9 = 77.05 69.59 = 77.05 69.59 = 77.05 69.59 = 77.05 70.59 = 1 64.38 = 64.05 79.24 = 77.33 79.24 = 77.33 79.24 = 77.33 71.37 = 77.35 71.37 = 77.55 71.33 = 17.55 71.33 = 17.55 71.37 = 77.55 71.33 = 17.55 71.33 = 17.55 71.37 = 77.55 71.35 = 77.55 71.55 = 77.55 71.55 = 77.55 = 7	.36 ; 11 = 1.08, 4 = 0.002 CE 5.23 0.02 To 5.23 0.47	33 24.28 33 def = 3 (P = 40 58.87 40 58.87 47 81.2 30 64.51 40 79.47 35 69.23 38 86.02 39 74.31 30 78.47 310 78.47 32 70.25 30 67.95 22 25.61 31 77.57 30 74.81.73 33 75.27 40 73.45	3.28 MA SDD 6.36 5.9 6.62 8.42 2.33 9.04 7.14 5.5 11.87 7.64 5.5 11.87 7.22 11.33 3.01 14.95 3.47 11.21	33 152 1 2 = 0% Total 40 47 30 40 40 40 40 40 40 40 40 40 4	23.1% Weight 6.1% 7.2% 3.6% 2.4% 9.9% 4.3% 4.2% 2.0% 10.1% 2.8% 3.6% 9.4% 9.5% 2.6% 6.7%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.47] -2.84 [-7.89, 2.21] -2.84 [-7.89, 2.21] -2.84 [-7.89, 2.21] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.83, -2.31] -1.45 [-4.87, 1.97] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.63, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69] -2.49 [-3.95, -1.03] -3.55 [-10.68, 3.58] -3.30 [-4.74, -1.86] -5.45 [-10.34, -0.56] -0.37 [-2.71, 1.97]	N	ACE MA	20
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2007) Li(2007) Li(2007) Li(2007) Li(2007) Li(2007) Li(2007) Li(2009) Wang(2006) Wang(2016) Wang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017)	0.00; Chi ² Z = 3.12 (f Mean 60.35 = 7 66.39 11 83.21 = 6 68.93 1 83.21 = 6 68.93 1 83.21 = 6 68.93 1 83.21 = 6 68.93 1 64.95 1 70.59 1 64.38 = 6 64.38 = 7 70.59 1 64.38 = 7 70.59 1 71.33 1 71.33 1 71.33 1 71.97 = 7 69.06 1 71.97 1 69.06 1 71.97 1 69.06 1 71.97 1 69.06 1 71.97 1 69.06 1 71.97 1 71.97 1 69.06 1 71.97 1 69.06 1 71.97 1 69.06 1 71.97 1 69.06 1 71.97 1 69.06 1 71.97 1 71.97 1 69.05 1 71.97	.36 11 11 = 1.08, (2 = 0.005 CE SD To S.23 5.23 9.41 0.02 3.08 8.46 8.47 3.002 3.08 8.43 7.49 5.54 2.74 8.28 3.07 7.41 2.241 1.11 1.12 2.41	33 24.28 33 ff = 3 (P = aff = 3 (P = 2) tal Mean 40 58.87 40 781.2 30 64.51 40 781.2 30 64.51 40 78.55 33 86.03 33 86.23 33 71.43 49 73.35 30 76.75 30 76.75 31 77.77 30 81.72.73 30 75.27 40 74.51 30 75.03 57	3.28 0.78); I MA <u>SD</u> 6.36 5.9 6.62 8.42 11.33 2.33 9.04 7.14 7.55 11.87 7.221 7.63 3.01 14.95 7.63 3.47 11.21 2.32	33 152 1 2 = 0% Total 40 47 30 40 47 30 40 40 40 40 40 40 40 40 40 4	23.1% 000.0% Weight 6.1% 3.7% 3.6% 9.9% 3.6% 9.9% 10.1% 2.8% 4.2% 7.1% 9.9% 10.1% 2.8% 6.7% 10.0%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] 4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -3.30 [-6.59, 0.39] -3.76 [-5.95, -1.68] -3.76 [-5.95, -1.68] -3.75 [-4.83, -2.31] -1.65 [-6.20, 3.08] 0.77 [-3.15, 4.69] -2.49 [-3.95, -1.03] -3.55 [-10.68, 3.58] -3.30 [-4.74, -1.86] -3.30 [-4.74, -1.86] -3.30 [-4.74, -1.86] -3.45 [-10.34, -0.56]	N	ACE MA	20
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Li(2007) Li(2007) Li(2009) Ren(2009) Wang(2013) You(2009) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2013) Total (95% CI) Heterogeneity: Tau ² = 1	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.89 79.34 66.39 18 32.21 77.02 69.59 69.59 70.59 1 64.38 70.59 1 64.38 70.59 1 64.38 79.24 71.33 11 71.97 69.06 1 74.66 1 74.66	$\begin{array}{c}$	33 24.28 33 24.28 34 ff = 3 (P = 20 20 141 Mean 40 58.87 47 81.2 30 64.51 40 78.62 30 74.31 30 74.33 30 73.55 32 60.22 30 77.33 30 77.57 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 75.03 57 df = 18 (P	3.28 0.78); I MA <u>SD</u> 6.36 5.9 6.62 8.42 11.33 2.33 9.04 7.14 7.55 11.87 7.221 7.63 3.01 14.95 7.63 3.47 11.21 2.32	33 152 1 2 = 0% Total 40 47 30 40 47 30 40 40 40 40 40 40 40 40 40 4	23.1% 000.0% Weight 6.1% 3.7% 3.6% 9.9% 3.6% 9.9% 10.1% 2.8% 4.2% 7.1% 9.9% 10.1% 2.8% 6.7% 10.0%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.47] -2.84 [-7.89, 2.21] -2.84 [-7.89, 2.21] -2.84 [-7.89, 2.21] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.83, -2.31] -1.45 [-4.87, 1.97] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.63, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69] -2.49 [-3.95, -1.03] -3.55 [-10.68, 3.58] -3.30 [-4.74, -1.86] -5.45 [-10.34, -0.56] -0.37 [-2.71, 1.97]	I IV.	ACE MA	
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2007) Li(2007) Li(2007) Li(2007) Li(2007) Li(2007) Li(2007) Li(2009) Wang(2006) Wang(2016) Wang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017)	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.89 79.34 66.39 18 32.21 77.02 69.59 69.59 70.59 1 64.38 70.59 1 64.38 70.59 1 64.38 79.24 71.33 11 71.97 69.06 1 74.66 1 74.66	$\begin{array}{c}$	33 24.28 33 24.28 34 ff = 3 (P = 20 20 141 Mean 40 58.87 47 81.2 30 64.51 40 78.62 30 74.31 30 74.33 30 73.55 32 60.22 30 77.33 30 77.57 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 75.03 57 df = 18 (P	3.28 0.78); I MA <u>SD</u> 6.36 5.9 6.62 8.42 11.33 2.33 9.04 7.14 7.55 11.87 7.221 7.63 3.01 14.95 7.63 3.47 11.21 2.32	33 152 1 2 = 0% Total 40 47 30 40 47 30 40 40 40 40 40 40 40 40 40 4	23.1% 000.0% Weight 6.1% 3.7% 3.6% 9.9% 3.6% 9.9% 10.1% 2.8% 4.2% 7.1% 9.9% 10.1% 2.8% 6.7% 10.0%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.47] -2.84 [-7.89, 2.21] -2.84 [-7.89, 2.21] -2.84 [-7.89, 2.21] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.83, -2.31] -1.45 [-4.87, 1.97] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.63, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69] -2.49 [-3.95, -1.03] -3.55 [-10.68, 3.58] -3.30 [-4.74, -1.86] -5.45 [-10.34, -0.56] -0.37 [-2.71, 1.97]	I IV.	ACE MA	
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Liu(2007) Liu(2007) Liu(2007) Liu(2009) Wang(2016) Wang(2013) You(2009) Zhang(2017) Zhang(2017) Zhang(2017) Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.89 79.34 66.39 18 32.21 77.02 69.59 69.59 70.59 1 64.38 70.59 1 64.38 70.59 1 64.38 79.24 71.33 11 71.97 69.06 1 74.66 1 74.66	$\begin{array}{c}$	33 24.28 33 24.28 34 ff = 3 (P = 20 20 141 Mean 40 58.87 47 81.2 30 64.51 40 78.62 30 74.31 30 74.33 30 73.55 32 60.22 30 77.33 30 77.57 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 75.03 57 df = 18 (P	3.28 0.78); I MA <u>SD</u> 6.36 5.9 6.62 8.42 11.33 2.33 9.04 7.14 7.55 11.87 7.221 7.63 3.01 14.95 7.63 3.47 11.21 2.32	33 152 1 2 = 0% Total 40 47 30 40 47 30 40 40 40 40 40 40 40 40 40 4	23.1% 000.0% Weight 6.1% 3.7% 3.6% 9.9% 3.6% 9.9% 10.1% 2.8% 4.2% 7.1% 9.9% 10.1% 2.8% 6.7% 10.0%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.47] -2.84 [-7.89, 2.21] -2.84 [-7.89, 2.21] -2.84 [-7.89, 2.21] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.83, -2.31] -1.45 [-4.87, 1.97] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.63, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69] -2.49 [-3.95, -1.03] -3.55 [-10.68, 3.58] -3.30 [-4.74, -1.86] -5.45 [-10.34, -0.56] -0.37 [-2.71, 1.97]	I IV.	ACE MA	
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Li(2007) Li(2007) Li(2009) Ren(2009) Wang(2013) You(2009) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Total (95% CI) Heterogeneity: Tau ² = 1	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.89 79.34 66.39 18.321 68.93 77.02 69.59 69.59 69.59 70.59 1 64.38 70.59 1 64.38 79.24 71.33 12 71.33 12 71.33 12 71.33 12 71.60 1 74.66 1 74.76 1 74.76 1 74.76 1 74.76 1 74.76 1 74.76 1 74.76 1 74.76 1 74.76 1 74.76 175.76 175.76 175.76 175.76 175.76 175.	.3.36 ; 11: = 1.08, (= 1.08, (> = 0.000 CE SD To SD To 5.23 3.41	33 24.28 33 24.28 34 ff = 3 (P = 20 20 141 Mean 40 58.87 47 81.2 30 64.51 40 78.62 30 74.31 30 74.33 30 73.55 32 60.22 30 77.33 30 77.57 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 74.78 30 75.03 57 df = 18 (P	3.28 MA SD 6.36 6.39 6.62 8.42 11.33 9.04 7.14 5.5 11.87 7.22 7.63 3.01 14.95 3.47 11.21 2.32 = 0.005	33 152 1 2 = 0% Total 40 47 30 40 47 30 40 40 40 40 40 40 40 40 40 4	23.1% 000.0% Weight 6.1% 3.7% 3.6% 9.9% 3.6% 9.9% 10.1% 2.8% 4.2% 7.1% 9.9% 10.1% 2.8% 6.7% 10.0%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.87, 1.97] -3.10 [-6.59, 0.39] -3.76 [-5.95, -1.57] 0.34 [-5.25, 55, -1.57] 0.35 [-10.68, 3.58] -3.30 [-4.74, -1.86] 5.45 [-10.34, -0.56] -0.37 [-2.71, 1.97] -2.28 [-3.16, -1.41]	I IV.	ACE MA	
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Li(2007) Li(2007) Li(2007) Li(2009) Ren(2009) Wang(2013) You(2009) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.89 77.02 67.9 63.91 83.21 77.02 67.9 70.50 70.50 70.	.36 :1 11 :1 12 :0 000 :0 11 :0 12 :0 12 :0 12 :0 12 :0 12 :0 12 :0 12 :0 12 :0 3.08 :0 8.46 :1 1.23 :0 2.41 :1 1.11 :1 1.11 :1 1.11 :1 1.11 :1 1.11 :1 1.11 :1 1.11 :1 1.11 :1 1.11 <td:1< td=""> 1.11 :1 1.11 <td:1< td=""> 1.11 :1 1.1 :1</td:1<></td:1<></td:1<></td:1<></td:1<></td:1<>	33 24.28 33 24.28 34 35 aff = 3 (P = 20 31 40 58.87 40 58.87 40 58.87 40 73.5 30 64.51 40 79.47 33 86.02 33 86.02 30 78.47 30 67.51 30 67.51 31 77.57 30 74.51 30 74.51 30 75.03 57 6f = 18 (P 01) 91	3.28 0.78); I MA 5.0 6.36 6.36 6.36 6.36 5.9 9.04 7.14 7.55 11.87 2.21 14.95 3.47 11.21 2.32 = 0.005 MA	33 152 1 ² = 0% 100 100 100 100 100 100 100 1	23.1% Weight 6.1% 7.2% 3.6% 2.4% 9.3.6% 4.3% 2.4% 2.0% 10.1% 2.8% 3.6% 4.2% 7.1% 2.0% 10.2% 10.5%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.87, 1.97] -3.10 [-6.59, 0.39] -3.76 [-5.95, -1.57] 0.34 [-5.32, 6.00] 0.357 [-4.83, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69] 0.35 [-10.68, 3.58] -3.30 [-4.74, -1.86] -5.45 [-10.34, -0.56] -0.37 [-2.71, 1.97] -2.28 [-3.16, -1.41] Mean Difference	I IV.	ACE MA	
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Liu(2007) Liu(2009) Wang(2010) Zhang(2017) Zhang(2017) Zhang(2017) Heterogeneity: Tau ² = 1 Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: Z D Study or Subgroup	0.00; Chi ² Z = 3.12 (f Mean 60.35 ± 76.6 66.89 ± 79.34 ± 66.39 11 83.21 ± 68.93 1 83.21 ± 68.93 1 77.02 ± 69.59 ± 70.59 1 64.05 ± 70.59 1 64.05 ± 78.34 ± 71.33 1 71.97 ± 69.06 1 74.66 ± 1.57; Chi ² ± z = 5.11 (F	$\begin{array}{ccc}$	33 24.28 33 def = 3 (P = 40 58.87 40 58.87 47 81.2 30 64.51 40 79.47 35 69.23 36 7.1 49 73.35 30 78.47 30 78.47 31 77.57 30 74.51 30 75.03 57 df = 18 (P 01) a	3.28 0.78); I MA SD 6.36 5.9 9.62 8.422 11.33 2.33 9.04 7.14 7.64 5.5 11.87 7.22 7.63 3.01 14.95 3.47 11.21 2.32 = 0.005 MA	33 152 1 2 = 0% Total 40 47 30 40 40 40 40 40 40 40 40 40 4	23.1% Weight 6.1% 7.2% 3.6% 2.4% 9.9% 4.3% 4.2% 2.0% 10.1% 2.8% 3.6% 9.4% 9.5% 2.8% 9.5% 2.8% 10.0% 10% 10% 10% 10% 10% 10% 10% 1	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference <u>IV, Random, 95% C</u> 1.48 [-107, 4.03] -4.60 [-3.67, -2.43] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.37, 1.97] -3.16 [-5.95, -1.57] 0.34 [-5.32, 6.00] -3.57 [-4.83, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69] -2.49 [-3.95, -1.56] 0.34 [-5.32, 6.00] 0.77 [-3.15, 4.69] -2.49 [-3.95, -1.68] -3.55 [-10.34, -0.56] -0.37 [-2.71, 1.97] -2.28 [-3.16, -1.41] Mean Difference <u>IV, Random, 95% CI</u>	I IV.	ACE MA	
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2007) Liu(2007) Liu(2007) Liu(2007) Liu(2007) Liu(2007) Liu(2007) Liu(2009) Wang(2013) You(2009) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 D Study or Subgroup Guo(2014)	0.00; Chi ² Z = 3.12 (f Mean 60.35 = 76.6 66.39 11 83.21 = 66.39 11 83.21 = 68.93 1 83.21 = 68.93 1 64.95 = 77.02 69.59 = 77.02 69.59 = 77.05 1 64.38 = 64.05 = 77.05 1 64.38 = 77.05 1 64.35 = 77.05 1 64.38 = 77.05 1 77.05 1 64.38 = 77.05 1 77.05	.36 :1 11: = 1.08, (2 = 0.002 CE SD To 5.23 8.37 9.41 0.02 3.08 8.46 4.31 7.49 5.54 8.37 2.41 1.11 6.12 6 = 36.97, (< 0.000	33 24.28 33 24.28 34 53 aff = 3 (P = 2) 20 tal Mean 40 58.87 40 58.87 40 78.12 30 64.51 40 79.47 31 70.47 32 70.25 30 77.57 30 77.57 30 75.23 40 74.51 33 75.27 df = 18 (P 01) 31 33 75.03 57 61 81 (P 01) 32 89.19	3.28 MA <u>SD</u> 6.36 6.99 6.62 8.422 11.33 9.04 7.54 5.5 11.87 7.22 2.33 9.04 7.54 5.5 11.87 7.22 2.33 3.01 14.95 3.47 11.21 2.32 = 0.005 MA SD 8.42 8.44 8.55 8.42 8.44 8.55 8.44 8.55 8.44 8.55 8.44 8.55 8.44 8.55 8.44 8.55	33 152 1 ² = 0% Total 40 40 47 30 40 40 40 47 33 39 21 36 64 49 32 30 30 21 26 30 30 21 26 51 27 51 71 72 75 75 75 75 75 75 75 75 75 75	23.1% 000.0% Weight 6.1% 7.2% 3.7% 3.6% 7.1% 2.4% 9.9% 7.1% 2.8% 7.1% 2.8% 6.7% 100.0% Weight 11.6%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] 4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -3.83 [-9.27, -1.49] -3.76 [-5.95, -1.57] 0.34 [-5.32, 6.00] -3.75 [-4.83, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69] -3.30 [-4.74, -1.86] -5.45 [-10.34, -0.56] -0.37 [-2.71, 1.97] -2.28 [-3.16, -1.41] Mean Difference IV. Random. 95% CI -4.17 [-8.13, -0.21]	I IV.	ACE MA	
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Li(2007) Liu(2007) Liu(2009) Ren(2009) Wang(2016) Wang(2013) You(2009) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 D Study or Subgroup Guo(2014) Li(2007)	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.89 183.21 66.39 183.21 66.39 183.21 66.39 183.21 69.59 69.59 69.59 70.59 164.38 70.59 164.38 70.59 164.38 79.24 71.33 71.37 71.37 71.37 71.37 71.37 71.37 71.57 71.57 71.57 71.57 71.57 71.57 72 55.57 72 55.57 72 55.57 72 55.57 72 75.57 75.	.36 :1 = 1.08, (. = 2 = 0.002 . CE	33 24.28 33 24.28 34 ff = 3 (P = 20 20 tal Mean 40 58.87 47 81.2 30 64.51 40 73.56 33 86.02 33 86.02 33 86.02 33 86.02 33 86.02 30 74.33 30 75.22 65.61 30 30 74.73 30 74.73 30 75.75 df = 18 (P 01) 55 305 89.19 36 88.1	3.28 0.78); I MA 5.02 6.36 6.36 5.92 6.36 5.92 6.32 8.42 2.33 9.04 7.14 5.5 11.87 2.23 7.62 5.5 11.87 2.33 9.04 5.5 3.47 11.21 2.32 3.47 3	33 152 1 ² = 0% Total 40 47 30 40 47 33 39 21 26 30 30 21 26 30 30 33 49 32 21 26 30 30 641 1 ² = 51 Total 1 ² = 51 Total 34 36	23.1% 000.0% Weight 6.1% 7.2% 3.6% 2.4% 7.1% 2.0% 10.1% 2.8% 3.6% 9.9% 4.3% 9.9% 4.2% 7.1% 2.0% 10.6% 9.5% 2.6% 0.0%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.87, 9.77] -3.10 [-6.59, 0.39] -3.76 [-6.59, 0.39] -3.76 [-6.59, 0.39] -3.76 [-6.59, 0.39] -3.76 [-6.38, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69] 0.35 [-10.38, -2.31] -3.55 [-10.88, -3.58] -3.30 [-4.74, -1.86] -0.37 [-2.71, 1.97] -2.28 [-3.16, -1.41] Mean Difference IV. Random. 95% CI -4.17 [-8.13, 0.21] -3.85 [-8.18, 0.48]	I IV.	ACE MA	
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2007) Li(2007) Li(2007) Li(2007) Li(2009) Ren(2009) Wang(2013) You(2009) Zhang(2017) Zhang(2017) Zhang(2017) Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 D Study or Subgroup Guo(2014) Li(2020)	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.89 79.34 79.34 83.21 66.39 183.21 77.02 69.59 70.59 1 64.38 70.59 1 64.05 1 70.59 1 64.05 1 70.59 1 64.38 7 70.59 1 64.38 7 7.02 7 7.059 1 64.38 7 7.059 1 7 7.059 1 7 7.059 1 7 7.33 1 7 7.133 1 7 7.137 1 7 4.66 6 1 7 7.139 1 7 7.137 1 7 4.66 1 7 7.137 1 7 4.57; Chi ² 2 5 5.11 (F Mean 8 8.02 8 8 8.02 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	$\begin{array}{c}$	33 24.28 33 24.28 34 ff = 3 (P = 40 58.87 40 58.87 40 79.47 35 69.23 30 64.51 40 73.56 30 74.31 30 78.47 31 77.57 30 74.51 30 75.03 57 df = 18 (P 01) 1.84 41 Mean 35 89.19 36 88.11 39 91.84	3.28 0.78); I MA <u>SD</u> 6.36 5.9 9.642 8.422 11.33 2.33 9.04 7.14 7.55 11.87 7.22 7.63 3.01 14.95 3.47 11.21 2.32 = 0.005 MA <u>SD</u> 8.02 9.62 4.84	33 152 1 2 = 0% Total 40 47 30 40 40 47 39 21 36 49 32 30 33 40 33 40 33 40 51 71 71 75 75 75 75 75 75 75 75 75 75	23.1% Weight 6.1% 7.2% 3.6% 2.4% 9.3.6% 4.3% 4.2% 7.1% 2.0% 10.1% 2.8% 3.6% 6.7% 10.0% 10.5% 11.6% 0.0	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference <u>IV, Random, 95% C</u> 1.48 [-107, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.44] -3.81 [-4.43, -1.49] -5.88 [-9.27, -1.49] -1.45 [-4.87, 1.97] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00] 0.77 [-3.15, 4.69] -2.49 [-3.95, -1.57] 0.34 [-5.32, 6.00] 0.77 [-3.15, 4.69] -2.49 [-3.95, -1.03] -3.55 [-10.68, 3.58] -3.30 [-4.74, -1.86] -5.45 [-10.84, -0.56] -0.37 [-2.71, 1.97] -2.28 [-3.16, -1.41] Mean Difference <u>IV, Random, 95% CI</u> -4.17 [-8.13, -0.21] -5.46 [-7.36, -3.56]	I IV.	ACE MA	
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2007) Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2005) Li(2007) Li(2007) Liu(2007) Liu(2009) Ren(2009) Wang(2016) Wang(2013) You(2009) Zhang(2017) Zhang(2017) Zhang(2017) Zhang(2017) Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 D Study or Subgroup Guo(2014) Li(2007)	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.89 183.21 66.39 183.21 66.39 183.21 66.39 183.21 69.59 69.59 69.59 70.59 164.38 70.59 164.38 70.59 164.38 79.24 71.33 71.37 71.37 71.37 71.37 71.37 71.37 71.57 Chi ² 2 = 5.11 (F Mean 85.02 8 85.02 8 84.25 9	$\begin{array}{c}$	33 24.28 33 24.28 34 ff = 3 (P = 40 58.87 40 58.87 40 79.47 35 69.23 30 64.51 40 73.56 30 74.31 30 78.47 31 77.57 30 74.51 30 75.03 57 df = 18 (P 01) 1.84 41 Mean 35 89.19 36 88.11 39 91.84	3.28 0.78); I MA <u>SD</u> 6.36 5.9 9.642 8.422 11.33 2.33 9.04 7.14 7.55 11.87 7.22 7.63 3.01 14.95 3.47 11.21 2.32 = 0.005 MA <u>SD</u> 8.02 9.62 4.84	33 152 1 2 = 0% Total 40 47 30 40 40 47 39 21 36 49 32 30 33 40 33 40 33 40 51 71 71 75 75 75 75 75 75 75 75 75 75	23.1% 000.0% Weight 6.1% 7.2% 3.6% 2.4% 7.1% 2.0% 10.1% 2.8% 3.6% 9.9% 4.3% 9.9% 4.2% 7.1% 2.0% 10.6% 9.5% 2.6% 0.0%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.87, 9.77] -3.10 [-6.59, 0.39] -3.76 [-6.59, 0.39] -3.76 [-6.59, 0.39] -3.76 [-6.59, 0.39] -3.76 [-6.38, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69] 0.35 [-10.38, -2.31] -3.55 [-10.88, -3.58] -3.30 [-4.74, -1.86] -0.37 [-2.71, 1.97] -2.28 [-3.16, -1.41] Mean Difference IV. Random. 95% CI -4.17 [-8.13, 0.21] -3.85 [-8.18, 0.48]	I IV.	ACE MA	
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2007) Li(2007) Li(2007) Li(2007) Li(2009) Ren(2009) Wang(2013) You(2009) Zhang(2017) Zhang(2017) Zhang(2017) Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 D Study or Subgroup Guo(2014) Li(2020)	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.89 79.34 79.34 83.21 66.39 183.21 77.02 69.59 70.59 1 64.38 70.59 1 64.05 1 70.59 1 64.05 1 70.59 1 64.38 7 70.59 1 64.38 7 7.02 7 7.059 1 64.38 7 7.059 1 7 7.059 1 7 7.059 1 7 7.33 1 7 7.133 1 7 7.137 1 7 4.66 6 1 7 7.139 1 7 7.137 1 7 4.66 1 7 7.137 1 7 4.57; Chi ² 2 5 5.11 (F Mean 8 8.02 8 8 8.02 8 8 8 0.28 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	$\begin{array}{c}$	33 24.28 33 24.28 34 ff = 3 (P = 20 20 tal Mean 40 58.87 47 81.2 30 64.51 47 81.2 33 86.02 33 86.02 33 86.20 39 74.31 30 78.47 30 78.47 30 75.22 65.61 33 30 75.75 df = 18 (P 01) 20 33 88.59 36 88.1 33 88.59	3.28 0.78); I MA <u>SD</u> 6.36 5.9 9.642 8.422 11.33 2.33 9.04 7.14 7.55 11.87 7.22 7.63 3.01 14.95 3.47 11.21 2.32 = 0.005 MA <u>SD</u> 8.02 9.62 4.84	33 152 1 2 = 0% Total 40 47 33 39 21 26 30 30 21 26 30 30 21 26 30 30 31 21 26 30 30 21 26 49 32 30 641 1 2 = 51 7 7 7 7 7 7 7 7 7 7 7 7 7	23.1% Weight 6.1% 7.2% 3.6% 2.4% 9.3.6% 4.3% 4.2% 7.1% 2.0% 10.1% 2.8% 3.6% 6.7% 10.0% 10.5% 11.6% 0.0	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference <u>IV, Random, 95% C</u> 1.48 [-107, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.44] -5.88 [-9.27, -1.49] -1.45 [-4.87, 1-97] -3.10 [-6.59, -1.57] 0.34 [-5.32, 6.00] 0.77 [-3.15, 4.69] -2.49 [-3.95, -1.57] 0.34 [-5.32, 6.00] 0.77 [-3.15, 4.69] -2.49 [-3.95, -1.57] 0.34 [-5.32, 6.00] 0.77 [-3.15, 4.69] -2.49 [-3.95, -1.03] -3.55 [-10.68, 3.58] -3.30 [-4.74, -1.86] -5.45 [-10.84, -0.56] -0.37 [-2.71, 1.97] -2.28 [-3.16, -1.41] Mean Difference <u>IV, Random, 95% CI</u> -4.17 [-8.13, -0.21] -3.85 [-8.18, 0.48] -5.46 [-7.36, -3.56]	I IV.	ACE MA	
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2019) Huang(2019) Huang(2020) Li(2007) Li(2007) Li(2007) Li(2009) Ren(2009) Wang(2013) You(2009) Zhang(2017) Zhang(2017) Zhang(2017)(1) Zhang(2017)(1) Zhang(2017)(1) Zhang(2017)(1) Zhang(2017)(1) Zhang(2017) Study or Subgroup Guo(2014) Li(2020) Zhang(2017) Li(2020) Zhang(2017)	0.00; Chi ² Z = 3.12 (f Mean 60.35 76.6 66.89 79.34 77.02 69.59 70.59 70.59 70.59 70.59 70.59 70.59 70.59 70.59 1 64.05 78.34 79.24 71.33 71.37 71.37 69.06 1 77.33 1 71.37 69.06 1 77.33 1 71.37 2 5.511 (F Mean 85.02 8 84.25 9 86.38 4 85.33 4	$\begin{array}{c}$	33 24.28 33 24.28 34 1 35 3 36 3 40 58.87 40 58.87 40 79.47 35 69.23 30 74.31 30 78.47 30 78.47 30 77.57 30 67.15 31 77.57 30 74.51 30 75.03 57 6 61 18 (P 01) 85 89.19 88.59 33 88.59 33 88.59 33 83.59	3.28 0.78); I MA SD 6.36 5.9 0.622 8.42 11.33 2.33 9.04 7.14 7.55 11.87 2.21 14.95 3.47 11.21 2.32 = 0.005 MA SD 8.02 4.84 6.26	33 152 1 2 = 0% Total 40 47 30 40 40 47 39 21 36 49 32 30 33 33 49 32 21 26 30 33 49 32 21 26 49 32 30 641 1; 2 = 57 7 7 7 7 7 7 7 7 7 7 7 7 7	23.1% 000.0% Weight 6.1% 7.2% 3.6% 2.4% 7.1% 2.0% 10.1% 2.8% 3.6% 9.9% 4.3% 9.9% 4.2% 7.1% 2.8% 3.6% 9.9% 4.2% 7.1% 2.8% 3.6% 9.9% 4.2% 7.1% 2.8% 3.6% 9.9% 4.2% 7.1% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.1% 2.8% 3.6% 9.9% 9.9% 9.9% 7.1% 2.8% 9.5% 9.5% 9.5% 7.1% 5.6% 9.5% 9.5% 5.6% 9.5% 5.6%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.87, -1.49] -3.10 [-6.59, 0.39] -3.76 [-6.59, -0.39] -3.76 [-6.38, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69] 0.35 [-10.34, -0.56] -0.37 [-2.71, 1.97] -2.28 [-3.16, -1.41] Mean Difference IV. Random. 95% CI -4.17 [-8.13, -0.21] -3.26 [-7.36, -3.56] -3.26 [-5.80, -0.72]	н ту 	ACE MA	0
Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 C Study or Subgroup Chen(2016) Deng(2014) Ge(2015) Guo(2014) Huang(2020) Li(2007) Li(2007) Li(2007) Li(2007) Li(2007) Li(2007) Li(2007) Li(2009) Wang(2013) You(2009) Zhang(2017) Zhang(2017) Zhang(2017) Total (95% CI) Heterogeneity: Tau ² = 1 Test for overall effect: 2 D Study or Subgroup Guo(2014) Li(2007) Li(2020) Zhang(2017) Total (95% CI)	0.00; Chi ² Z = 3.12 (f Mean 60.35 = 76.6 66.89 = 70.6 = 68.93 = 70.59 = 70.50 = 70.5	$\begin{array}{c}$	33 24.28 33 24.28 34 ff = 3 (P = 20 20 tal Mean 40 58.87 40 58.87 40 781.2 30 64.51 40 781.2 30 64.51 40 78.52 30 74.31 30 78.47 30 77.57 30 71.757 30 74.88 33 75.27 df = 18 (P 01) 30 57 6f = 18 (P 33 88.59 34 88.59 35 81.9 36 88.1 37 91.9 38 85.59 33 81.59 33 41.9 33 81.9 34 51.9	3.28 0.78); I MA SD 6.36 5.9 0.622 8.42 11.33 2.33 9.04 7.14 7.55 11.87 2.21 14.95 3.47 11.21 2.32 = 0.005 MA SD 8.02 4.84 6.26	33 152 1 2 = 0% Total 40 47 30 40 40 47 39 21 36 49 32 30 33 33 49 32 21 26 30 33 49 32 21 26 49 32 30 641 1; 2 = 57 7 7 7 7 7 7 7 7 7 7 7 7 7	23.1% 000.0% Weight 6.1% 7.2% 3.6% 2.4% 7.1% 2.0% 10.1% 2.8% 3.6% 9.9% 4.3% 9.9% 4.2% 7.1% 2.8% 3.6% 9.9% 4.2% 7.1% 2.8% 3.6% 9.9% 4.2% 7.1% 2.8% 3.6% 9.9% 4.2% 7.1% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.2% 3.6% 7.1% 2.8% 3.6% 9.9% 9.9% 9.9% 7.1% 2.8% 9.5% 9.5% 9.5% 7.1% 5.6% 9.5% 9.5% 5.6% 9.5% 5.6%	-0.73 [-2.11, 0.65] -1.06 [-1.72, -0.39] Mean Difference IV. Random. 95% C 1.48 [-1.07, 4.03] -4.60 [-6.76, -2.44] 2.38 [-1.44, 6.20] -0.13 [-4.04, 3.78] -2.84 [-7.89, 2.21] -2.81 [-4.13, -1.49] -5.38 [-9.27, -1.49] -1.45 [-4.87, -1.49] -3.10 [-6.59, 0.39] -3.76 [-6.59, -0.39] -3.76 [-6.38, -2.31] -1.56 [-6.20, 3.08] 0.77 [-3.15, 4.69] 0.35 [-10.34, -0.56] -0.37 [-2.71, 1.97] -2.28 [-3.16, -1.41] Mean Difference IV. Random. 95% CI -4.17 [-8.13, -0.21] -3.26 [-7.36, -3.56] -3.26 [-5.80, -0.72]	I IV.	ACE MA	0

Figure 2. Forest plot of ACE versus MA. (A) Total effective rate, (B) Body mass index, (C) Body weight, (D) Waist circumference. ACE = acupoint catgut embedding, CI = confidence interval, MA = manual acupuncture, SD = standard deviation.

	ACE	ACE EA				Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-	-H, Random, 95% Cl
Chen(2014)	28	28	21	28	2.8%	1.33 [1.06, 1.65]		
Chen(2018)	24	30	23	30	2.0%	1.04 [0.80, 1.36]		
Chu(2014)	16	25	18	25	1.0%	0.89 [0.61, 1.30]		
Guo(2013)	25	28	25	28	3.9%	1.00 [0.83, 1.20]		
Hu(2014)	26	30	25	30	3.0%	1.04 [0.84, 1.29]		
Huang(2007)	25	30	19	30	1.5%	1.32 [0.96, 1.80]		
Huang(2009)(1)	27	30	26	30	3.8%	1.04 [0.86, 1.25]		
Kang(2007)	20	30	19	30	1.1%	1.05 [0.73, 1.53]	_	· · · ·
Lan(2016)	97	100	98	100	16.4%	0.99 [0.95, 1.03]		-
Li(2014)	30	41	29	41	1.9%	1.03 [0.79, 1.36]		
Li(2016)	50	50	40	50	5.6%	1.25 [1.08, 1.44]		
Lin(2012)	23	30	25	30	2.2%	0.92 [0.71, 1.19]		
Lv(2006)	39	45	31	45	2.6%	1.26 [1.00, 1.58]		
Qin(2008)	26	30	27	30	3.8%	0.96 [0.80, 1.16]		
Ren(2016)	32	36	29	36	3.4%	1.10 [0.91, 1.34]		
Wang(2001)	59	60	27	30	6.8%	1.09 [0.97, 1.24]		
Wang(2008)	28	30	28	30	6.1%	1.00 [0.87, 1.14]		
Wu(2017)	66	76	59	73	5.6%	1.07 [0.93, 1.24]		
Yan(2015)	25	27	24	26	5.0%	1.00 [0.86, 1.17]		
Yang(2014)	24	29	24	28	2.7%	0.97 [0.77, 1.21]		
Zhang(2011)	29	30	26	30	4.9%	1.12 [0.95, 1.30]		
Zhang(2016)	25	30	24	30	2.4%	1.04 [0.82, 1.32]		
Zhou(2016)	39	40	35	40	6.6%	1.11 [0.98, 1.27]		
Zhou(2020)	40	45	39	45	5.0%	1.03 [0.88, 1.20]		
Total (95% Cl)		930		895	100.0%	1.06 [1.02, 1.10]		◆
Total events	823		741					
Heterogeneity: Tau ² =	0.00; Chi ²	= 30.2	4, df = 23	(P = 0	.14); I² = 2	4%		
Test for overall effect:	•						0.5 0.7	1 1.5 2
	· · · ·		,					EA ACE

Figure 3. Forest plot of the total effective rate in the comparison ACE versus EA. ACE = acupoint catgut embedding, CI = confidence interval, EA = electroacupuncture.

A	ACE+EA EA							Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV	Random, 9	5% CI	
Lan(2016)	24.58	3.81	100	27.81	3.18	100	55.9%	-3.23 [-4.20, -2.26]			-		
Lin(2012)	25.27	4.35	30	27.85	3.82	30	12.3%	-2.58 [-4.65, -0.51]					
Zong(2009)	23.67	3.18	50	26.81	3.39	50	31.8%	-3.14 [-4.43, -1.85]			-		
Total (95% CI)			180			180	100.0%	-3.12 [-3.85, -2.39]			•		
Heterogeneity: Tau ² =	0.00; Cł	ni² = 0.	31, df =	= 2 (P =	0.86);	l² = 0%	, D		H	10		10	2
Heterogeneity: Tau ² = 0.00; Chi ² = 0.31, df = 2 (P = 0.86); $I^2 = 0\%$ Test for overall effect: Z = 8.42 (P < 0.00001)									-20 -10 0 10 ACE+EA EA				

В	A	CE+EA	4		EA			Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, F	andom, 95	% CI	
Lan(2016)	82.93	8.64	100	89	8.09	100	60.7%	-6.07 [-8.39, -3.75]			-		
Lin(2012)	77.13	8.04	30	83.88	13.57	30	10.3%	-6.75 [-12.39, -1.11]					
Zong(2009)	83.01	8.57	50	88.8	8.55	50	29.0%	-5.79 [-9.15, -2.43]			-		
Total (95% CI)			180			180	100.0%	-6.06 [-7.87, -4.25]		•			
Heterogeneity: Tau ² =				`	0.96); l [;]	² = 0%			-20	-10	0	10	20
Test for overall effect:	Z = 6.57	' (P < (0.00001	1)					ACE+EA EA				

Figure 4. Forest plot of the total effective rate in the comparison ACE plus EA versus EA. (A) Body mass index, (B) Waist circumference. ACE = acupoint catgut embedding, CI = confidence interval, EA = electroacupuncture, SD = standard deviation.

3.3.11. Quality of the evidence. The systematic analysis examined eight outcomes for the intervention and control groups (Supplemental Digital Content 6–11, http://links.lww. com/MD/H826). Total effective rate, BMI, BW, WC, HC, WHR, BFP were the main outcomes, and TC and triglyceride levels were the secondary outcomes. The GRADE profile of all outcomes was moderate, very low, or low.

4. Discussion

4.1. Principal findings

In this SR, we identified 73 studies on ACE for obesity involving 5872 participants. We examined various combinations of ACE, used either alone or as an adjunctive intervention, versus controls for the treatment of obesity, measured by BMI, BW, HC, WC, WHR, BFP, and total effective rate. ACE was clinically effective in reducing obesity when compared with MA alone. This finding is similar to that of a previous study.^[12] Moreover, ACE plus EA was better than EA alone. However, there was no significant difference in the other comparison groups. With regard to the comparison of ACE versus EA alone, although we included a relatively large sample size (n = 795), our meta-analysis showed no significant difference in some outcomes. The reason might be that EA involves the use of pulse currents sent by specific instruments to achieve a therapeutic effect. In the presence of acupuncture, the pulse current can be increased with continuous stimulation of the needle. A strong stimulation has a qi equivalent to the effect of acupuncture.^[82] Further, ACE plus MA was better in reducing obesity than MA in terms of the total effective rate with a large sample size (n = 574) but the other outcomes were not statistically significant since only two studies reported the desired outcomes. With regard to ACE plus AA versus AA alone, our meta-analysis showed that ACE plus AA was beneficial for reducing obesity; however, only two studies assessed this aspect. In comparing ACE plus cupping therapy versus cupping therapy, combination therapy appeared better than cupping therapy alone, but there were limited data available to pool. The comparison of ACE plus CMT versus CMT included 430 patients, and ACE plus CMT was better, but only three trials were evaluated. Thus, further analysis is needed.

4.2. Strengths and limitations

This SR and meta-analysis had several strengths. We searched not only international databases but also Chinese, Korean, and Japanese databases to find the included articles. Furthermore, the included studies used common clinical evaluation tools for measuring obesity. Moreover, we provided a comprehensive review of the effects of ACE, while considering possible sources of heterogeneity. We also used GRADEPRO to explore the quality of evidence for each outcome. Two SRs on the efficacy of ACE on obesity have previously been conducted, and they were published in 2015^[12] and 2019.^[13] However, our SR was different from these two SRs. In particular, the first review^[12] analyzed 43 studies by separating the treatment types into ACE, MA, EA, and drugs alone, with a small sample size. The second review^[13] analyzed 15 studies, with a focus on abdominal obesity, and did not include simple obesity.

This review has several limitations. First, there was a paucity of high-quality RCTs. Half of the trials did not employ allocation concealments, and none blinded the acupuncturists and participants due to the inherent characteristic of the ACE intervention. These poor-quality studies could lead to imprecise evidence. Second, there was substantial heterogeneity among the pooled trials, and we tried to reduce the heterogeneity by synthesizing the data separately based on the characteristics for subgroup analysis; however, there was unresolved heterogeneity in some comparison groups. The treatment duration, selection of acupoints, and study characteristics could influence the results of the trials and could not resolve the heterogeneity. In addition, ACE involves stimulating acupoints in the skin, which makes patients feel the "qi" gradually; therefore, long-term effects need to be assessed.^[93] However, only few trials evaluated the follow-up of patients, underscoring the need for more studies on the long-term effects of ACE.

4.3. Future research and clinical application

Given the above limitations, further well-designed RCTs with high-quality evidence are needed to assess the efficacy of ACE for obesity. First, the RCTs should ensure generation of accurate random sequences and should blind the participants and practitioners to reduce bias. The clinical trials can also be registered with clinical trial platforms in advance. Second, the details of the studies should be reported thoroughly, especially, the results of changes in efficacy. Third, the effect of ACE with sham or placebo must also be explored.

Furthermore, we hope this SR will motivate governments and clinicians to support the use of ACE in the management of obesity. As previously stated, ACE is less costly and more convenient for therapists. However, ACE is not approved by the National Health Insurance program in South Korea, which hinders its use by practitioners. Thus, the government should provide more support to make ACE a popular practice throughout society. In clinical practice, ACE is usually combined with other acupuncture therapies, like MA, EA cupping therapy, or CMT.^[94] This review can help guide therapists to strongly recommend the use of ACE alone or ACE plus EA to better manage obesity.

5. Conclusions

Finally, we comprehensively evaluated the treatment effects of ACE and other therapies. ACE had a moderate effect compared to that of MA alone in the treatment of obesity. For combination therapy, ACE and EA are the best choice in clinical practice. Despite some indications of potential improvement of body mass index, body weight and other obesity related outcomes, the evidence regarding the effectiveness and efficacy of ACE for simple is of poor quality and therefore inconclusive. Although our review provided low-quality evidence and heterogeneity, it can serve as a helpful guide for public health practice.

Author contributions

Conceptualization: Sungha Kim, Mi Ju Son. Data extraction: Hui Yan Zhao, Mi Ju Son. Investigation: Hui Yan Zhao, Mi Ju Son. Methodology: Mi Ju Son. Supervision: Sungha Kim, Mi Ju Son. Visualization: Hui Yan Zhao, Mi Ju Son.

- Writing original draft: Hui Yan Zhao.
- Writing review & editing: Sungha Kim, Mi Ju Son.

References

- Shetty P, Schmidhuber J. Introductory lecture the epidemiology and determinants of obesity in developed and developing countries. Int J Vitam Nutr Res. 2006;76:157–62.
- [2] Ataey A, Jafarvand E, Adham D, et al. The relationship between obesity, overweight, and the human development index in World Health Organization Eastern Mediterranean Region Countries. J Prev Med Public Health. 2020;53:98–105.
- [3] Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012;42:563–70.
- [4] Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127:1–4.
- [5] Bosy-Westphal A, Müller MJ. Diagnosis of obesity based on body composition-associated health risks-time for a change in paradigm. Obes Rev. 2021;22(Suppl 2):e13190.
- [6] Bray GA, Frühbeck G, Ryan DH, et al. Management of obesity. Lancet. 2016;387:1947–56.
- [7] Lang A, Froelicher ES. Management of overweight and obesity in adults: behavioral intervention for long-term weight loss and maintenance. Eur J Cardiovasc Nurs. 2006;5:102–14.
- [8] Mitchell PB, Morris MJ. Depression and anxiety with rimonabant. Lancet. 2007;370:1671–2.
- [9] Lee YS, Han CH, Lee JY. A literature review on the study of thread embedding acupuncture in domestic and foreign journals. J Prev Med Public Health. 2016;20:93–113.
- [10] Gao L, Kong XJ, Shi X. Effects of electroacupuncture and acupoint catgut-embedding on mRNA expression of lipid metabolism gene PPARgamma and related lipase of rats with simple obesity. Zhongguo Zhen Jiu. 2011;31:535–8.

- [11] Inprasit C, Huang YC, Lin YW. Evidence for acupoint catgut embedding treatment and TRPV1 gene deletion increasing weight control in murine model. Int J Mol Med. 2020;45:779–92.
- [12] Guo T, Ren Y, Kou J, et al. Acupoint catgut embedding for obesity: systematic review and meta-analysis. Evid Based Complement Alternat Med. 2015;2015:401914.
- [13] Sheng J, Jin X, Zhu J, et al. The effectiveness of acupoint catgut embedding therapy for abdominal obesity: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2019;2019:9714313.
- [14] Li HX, Chen NN. Clinical study of acupoint catgut embedding therapy in the treatment of abdominal obesity with hyperlipidemia. JCAM. 2020;36:29–33.
- [15] Zhou W, Zhou ZY, Hu F, et al. Clinical comparative study on electroacupuncture and acupoint catgut embedding therapy for treatment of simple obesity. Liaoning J Tradit Chin Med. 2020;47:156–9.
- [16] Chen L, Cong D, Wang G, et al. Tuina combined with diet and exercise for simple obesity: a protocol for systematic review. Medicine (Baltimore). 2022;101:e28833.
- [17] Zhang RQ, Tan J, Li FY, et al. Acupuncture for the treatment of obesity in adults: a systematic review and meta-analysis. Postgrad Med J. 2017;93:743–51.
- [18] Salameh JP, Bossuyt PM, McGrath TA, et al. Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist. BMJ. 2020;370:m2632.
- [19] Zhao HY, Kim S, Yang C, et al. Comparing acupoint catgut embedding and acupuncture therapies in simple obesity: a protocol for systematic review and meta-analysis. Med Case Rep Study Protoc. 2021;2:e0194.
- [20] Higgins JPT, Savović J, Page MJ, et al. Chapter 8: assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, et al. eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021), Cochrane; 2021. Available at: www.training.cochrane.org/handbook [access date January 3, 2022].
- [21] Morche J, Conrad S, Passon A, et al. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. Z Evid Fortbild Qual Gesundhwes. 2018;133:58–66.
- [22] Chen F, Wu S, Zhang Y. Effect of acupoint catgut embedding on TNF-α and insulin resistance in simple obesity patients. Acupunct Res. 2007;32:49–52.
- [23] Chen JY. Clinical Observation on Acupuncture Combined with Dachangshu Points Catgut Embedding Therapy for Simple Obesity Combined with Constipation [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2010.
- [24] Chen XX. Clinical Effect Observation of Treating Central Obesity with Electric Needle Acupuncture Plus Catgut Embedding [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2010.
- [25] Chen Y. 28 cases of catgut embedding therapeutic acupoints. Chin Med Modern Distance Educ China. 2014;12:69–70.
- [26] Chen YY, Li NF, Cui C, et al. Observation on the clinical effect of acupuncture combined with catgut embedding on acupoints in the treatment of simple obesity. Guangming Tradit Chin Med. 2015;30:1266–8.
- [27] Chen RZ. Clinical study on acupoint catgut embedding therapy on simple obesity. J Clin Med. 2016;3:8506–7.
- [28] Chen ZR. Clinical Study on the Treatment of Simple Obesity Complicated Fatty Liver by Acupoint Catgut Embedding Therapy [master degree]. Anhui, China: Anhui University of Chinese Medicine; 2018.
- [29] Chen YH, Chen ZL, Feng ZG, et al. Clinical observation on obesity and hyperlipidemia in patients treated by acupoint catgut-embedding therapy based on the theory of "Interconnection of Zang-Fu Viscera." Chin J General Pract. 2019;17:2092–5.
- [30] Chu XY, Xu SF. Effects of acupoint catgut embedding therapy versus electroacupuncture therapy on body weight and shape in female. Shanghai J Acu-Mox. 2014;33:636–7.
- [31] Deng LJ, Lun ZJ, MA XW, et al. Clinical observation on regulating the three energizer by acupoint catgut embedding combined with abdominal acupuncture in treating abdominal obesity: a randomized controlled trial. World J Acupunct-Mox. 2014;24:29–34.
- [32] Ding M, Ma YP, Wang YJ. Clinical observation of catgut implantation at acupoint on 65 cases of simple obesity. Modern J Integr Tradit Chin West Med. 2006;15:3337–450.
- [33] Fan WY, Liu XR, Zhou XH. Treatment of simple obesity with eight acupoints around the navel clinical research on the regulation of insulin resistance. Lishizhen Med Materia Medica Res. 2010;21:945–7.

- [34] Ge BH, Wang XY, Zhang T, et al. Effect of acupoint thread embedding on blood lipids and insulin in simple obesity. Shanghai J Acu-Mox. 2015;34:117–9.
- [35] Guo RL. The Clinical Research of Thread Embedding Therapy Combined with Auricular Acupressure for the Obesity Feature Dampness Accumulation Due to Spleen Deficiency [master degree]. Guangzhou, China: Guangzhou university of Chinese Medicine; 2011.
- [36] Guo JH. Clinical Observation of Catgut Implantation at Acupoint on the Treatment of Simple Obesity in Stagnation of Live-qi Type [master degree]. Shandong, China: Shandong University of Chinese Medicine; 2013.
- [37] Guo XL. Clinical Effect Observation of Treating Spleen Dampness Constipation Obesity with Acupuncture and Catgut Embedding [master degree]. Chengdu, China: Chengdu University of Chinese Medicine; 2014.
- [38] Hou SJ. Simple obesity treated by acupuncture combined with catgut embedding: 68 cases. Chin J Ethnomed Ethnopharm. 2016;25:74–6.
- [39] Hu PJ, Cheng HL, Chu HR. Clinical study on acupoint catgut embedding in the treatment of simple obesity complicated with dyslipidemia. Clin J Tradit Chin Med. 2013;25:1066–8.
- [40] Hu PJ. Clinical Research for the Simple Obesity with Dyslipidemia by the Method of Acupoint Catgut Embedding [master degree]. Anhui, China: Anhui University of Chinese Medicine; 2014.
- [41] Huang Y. The Case-control Study on the simple Obesity of Insufficiency of the Spleen Syndrome Treated by Catgut Implantation at Acupoint and Acusector [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2007.
- [42] Huang XS. Influence of Acupuncture Combined with Acupoint Catgut Embedding of Obesity with Retarded Menstrustion [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2009.
- [43] Huang LC. The Curative Effect Observation and Cost-benefit Analysis of Curing Simple Obesity by Catgut Embedding [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2009.
- [44] Huang QZ. Clinical Observation of Catgut Implantation at Shu-mu Points in Treating Simple Obesity [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2019.
- [45] Huang J. The effect of catgut embedding at acupoint on weight and blood lipids OD patients with simple obesity. J Extern Ther Tradit Chin Med. 2020;29:52–3.
- [46] Kang QL. The Clinical Analysis on Acupint Catgut Embedding of Simple Obesity [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2007.
- [47] Lan DC, Xu NG, Xun J, et al. Randomized controlled trial of electro-acupuncture combined with acupoint thread-embedding for treatment of abdominal obesity. J Guangzhou Univ Tradit Chin Med. 2016;33:189–93.
- [48] Li XR. Clinical Study about the Effect of Leptin and Blood-lipid with Catgut Implantation at Acupoint on Curing Obesity [master degree]. Shandong, China: Shandong University of Chinese Medicine; 2005.
- [49] Li J, Tian BG. Observation on the therapeutic effect of 63 cases of simple obesity treated by differentiation of symptoms and acupoints and catgut embedding. New Chin Med. 2007;6:43–4.
- [50] Li ZY, Lu PS. Clinical comparative study on acupuncture combined with acupoint catgut embedding for treatment of simple obesity. JCAM. 2009;25:1–3, 63.
- [51] Li HY. Advantage research of catgut embedding for treatment of simple obesity. Guide China Med. 2012;10:409–10.
- [52] Li YY, Hu H, Liang CM. Therapeutic observation of acupoint thread-embedding for abdominal obesity. Shanghai J Acu-Mox. 2014;33:44–6.
- [53] Li LJ, Li YJ, Lin DF. Therapeutic effect of acupoint catgut embedding on simple obesity of spleen deficiency and dampness resistance. J Baotou Med College. 2016;32:105–6.
- [54] Lin GF. The Clinical Research of Jin Three-Needle Therapy for the Simple Obesity Patients [PhD degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2012.
- [55] Lin SS, Chen HY. Observation on the clinical curative effect of 100 cases of acupoint catgut embedding combined with cupping for lose weight. Asia-Pacific Tradit Med. 2015;11:92–3.
- [56] Liu YZ, Xu LL. Therapeutic effect of embedding catgut in acupoint to treat simple obesity. J Nurs Sci. 2007;22:34–5.
- [57] Liu QW. The Clinical Study of Using Acupoint Catgut Implantation in the Treatment of Simple Obesity [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2009.
- [58] Luo LQ. Simple obesity application acupoints study on the effect of thread embedding treatment. Med Forum. 2016;20:212–3.
- [59] Lv W. A Comparative Study of Thread Embedding and Eletroacupuncture in the Treatment of Simple Obesity [master degree]. Nanjing, China: Nanjing University of Chinese Medicine; 2006.

- [60] Mai YL. Clinical observation on treating obesity by acupoint catgut embedding therapy. Clin J Chin Med. 2013;5:46.
- [61] Meng S, Chen W. Acupoint catgut embedding treating 48 cases of simple obesity-compared with 48 cases of acupuncture treatment. Zhejiang J Tradit Chin Med. 2005;8:363.
- [62] Qiao L. Observation on the clinical effect of catgut embedding at acupoint for simple obesity. World Latest Med Info. 2016;16:112–5.
- [63] Qin Z. Clinical Study of Acupoint Catgut Implantation for Simple Obesity [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2008.
- [64] Ren BY. Clinical Study of ShuMu Combination by the Acupoint Catgut Embedding Therapy on Obesity of Phlegm-dampness Syndrome [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2009.
- [65] Ren CC, Ge BH. Comparative study on the efficacy maintenance time between acupoint thread embedding and electroacupuncture for simple obesity. Shanghai J Acu-Mox. 2016;35:1299–302.
- [66] Shang DJ, Li Y, Feng KY. "Eight points for weight loss" acupoint catgut embedding combined with strengthening the spleen and removing dampness Tuina therapy for simple obesity (Spleen deficiency and dampness type) curative effect observation. Guid J Tradit Chin Med Pharm. 2016;22:57–9.
- [67] Shen W, Qiu L, Xie Y, et al. Clinical observation on catgut implantation at acupoint for treatment of simple obesity. JCAM. 2012;28:6–7.
- [68] Song YX, Wang L, Ma Z. Clinical study on acupoint catgut embedding combined with abdominal massage in treatment of female abdominal obesity with spleen deficiency and dampness retention syndrome. Int J Trad Chin Med. 2018;40:1150–3.
- [69] Sun FJ. Exploration for the effectiveness traditional Chinese medicine syndrome differentiation combined with acupoint catgut embedding in the treatment of simple obesity. Elec J Clin Med Lit.2020;7:38–40.
- [70] Tang CL, Dai DC, Zhao GF, et al. Clinical observation on electroacupuncture combined with catgut implantation at acupoints for treatment of simple obesity of heart and spleen deficiency type. Chin Acup Moxib. 2009;29:703–7.
- [71] Wang GM, Li LX, Song YQ, et al. Therapeutic effects of 60 cases of simple obesity treated with acupoint catgut embedding therapy. Chin Acup Moxib. 2001;7:11–2.
- [72] Wang XY. Clinical Study on the Effect of Secrum Insulin ANF Bloodlipid with Catgut Implantation at Acupoint on Treating Simple Obesity [master degree]. Shandong, China: Shandong University of Chinese Medicine; 2006.
- [73] Wang SS. Observation on clinical curative effect of catgut implantation at acupoint intervention to treat patients with simple obesity. Chin Nur Res. 2006;17:1558–9.
- [74] Wang J. Clinical Analysis on Acupoint Catgut-embedding Therapy for Abdominal Obesity [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2008.
- [75] Wang J, Pan WY. Clinical research on electro-acupuncture plus catgut implantation at acupoint for treatment of 40 simple obesity cases. J Tradit Chin Med. 2011;52:1023–5.
- [76] Wang L. Clinical Study on Catgut Embedding at Acupoints for Simple Obesity [Master degree]. Beijing, China: Beijing University of Chinese Medicine; 2013.
- [77] Wang HZ. 30 cases of simple obesity treated by acupoint catgut embedding and auricular acupressure. J Extern Ther of Tradit Chin Med. 2013;22:24–5.

- [78] Wen JF, Li Z. Clinical study on acupuncture combined with catgut embedding at acupoints in the treatment of simple obesity. JCAM. 2013;29:21–2.
- [79] Wu XN, Liu MF, Xiong YL. Clinical research on catgut embedding in the treatment of simple obesity with back-shu and Front-Mu points. Guangming Tradit Chin Med. 2017;32:400–3.
- [80] Xu YL. Three Fat Needle Acupuncture Point Catgut Embedding Combined with Clinical Research on Acupuncture Treatment of Simple Obesity in Adults [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2015.
- [81] Xue HX. Observation on curative effect of 25 cases of acupoint catgut embedding for weight loss. Nei Mongol J Tradit Chin Med. 2017;36:86.
- [82] Yan XR. Clinical Research of Contrast of Acupoint Thread-embedding Therapy and Electric Acupuncture Therapy in the Treatment of Simple Obesity [master degree]. Hubei, China: Hubei University of Chinese Medicine; 2015.
- [83] Yang TY. Clinical Observation of Acupoint Thread-embedding Therapy in the Treatment of Simple Obesity [master degree]. Hubei, China: Hubei University of Chinese Medicine; 2014.
- [84] Yin LL, Wang HR, Li CM, et al. Clinical observation on 30 Cases of senile simple obesity treated by acupoint catgut embedding therapy. Forum Tradit Chin Med. 2013;28:30–1.
- [85] You SF. The Clinical Research in Treating Simple Obesity by Acupoint Catgut Embedding [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2009.
- [86] Zhang JY. Randomized Controlled Trials on Treating Simple Obesity with Embedding Thread into Acupoint [Master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2011.
- [87] Zhang KY. A Clinical Observation on Treating Simple Obesity by Catgut Implantation on Fat 3-needle Therapy [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2016.
- [88] Zhang Y. The Study of Clinical Effect in Treating Simple Obesity of Splenasthenic Fluid-retention with Catgut Implantation at Acupoint [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2017.
- [89] Zhang H, Ding TH. The effect of acupoint catgut embedding on simple obesity and its influence on blood lipids. Modern J Integr Tradit Chin West Med. 2017;26:1334–6.
- [90] Zheng KW. The Clinical Study on Clinical Effects, Blood Lipids and Blood Sugar of Simple Obesity Treated by Catgut Implantation and Auricular Acupressure [PhD degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2013.
- [91] Zhou YB, Jiang H, Han G, et al. Clinical Analysis of Catgut Embedding Acupoints in the Treatment of Leg Obesity due to Spleen Deficiency and Phlegm-dampness. Woman's Health Research; 2016;2:223–4.
- [92] Zong GJ. Clinical Analysis on Acupoint Catgut-embedding Therapy for Abdominal Obesity [master degree]. Guangzhou, China: Guangzhou University of Chinese Medicine; 2009.
- [93] Li QZ, Luo XJ. Clinical observation of acupoint catgut embedding in the treatment of simple obesity (stomach Heat and Spleen Stagnation syndrome) by influencing blood GLP-1 concentration. J Pract Tradit Chin Med. 2021;35:69–72.
- [94] Lee HG, Im JG, Jung DJ, et al. Case report on 4 patients with lumbar discherniation treated with concurrent embedding therapy under conventional Korean Medical treatments. J Physiol Pathol Korean Med. 2013;27:124–9.